1
|
Cosson C, Riou R, Patoli D, Niu T, Rey A, Groslambert M, De Rosny C, Chatre E, Allatif O, Henry T, Venet F, Milhavet F, Boursier G, Belot A, Jamilloux Y, Merlin E, Duquesne A, Grateau G, Savey L, Jacques Maria AT, Pagnier A, Poutrel S, Lambotte O, Mallebranche C, Ardois S, Richer O, Lemelle I, Rieux-Laucat F, Bader-Meunier B, Amoura Z, Melki I, Cuisset L, Touitou I, Geyer M, Georgin-Lavialle S, Py BF. Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation. J Exp Med 2024; 221:e20231200. [PMID: 38530241 DOI: 10.1084/jem.20231200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 12/22/2023] [Accepted: 02/27/2024] [Indexed: 03/27/2024] Open
Abstract
NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development.
Collapse
Affiliation(s)
- Camille Cosson
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Romane Riou
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Danish Patoli
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Tingting Niu
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University , Shanghai, China
| | - Amaury Rey
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Marine Groslambert
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Charlotte De Rosny
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Elodie Chatre
- Univ Lyon, ENS de Lyon, Inserm, CNRS SFR Biosciences US8 UAR3444, Université Claude Bernard Lyon 1 , Lyon, France
| | - Omran Allatif
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Thomas Henry
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Fabienne Venet
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| | - Florian Milhavet
- Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France
- Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
| | - Guilaine Boursier
- Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France
- Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
| | - Alexandre Belot
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
- Pediatric Nephrology, Rheumatology, Dermatology Department, National Referee Centre for Rheumatic and Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
- Lyon Immunopathology Federation (LIFE), Université Claude Bernard Lyon 1 , Lyon, France
| | - Yvan Jamilloux
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
- Lyon Immunopathology Federation (LIFE), Université Claude Bernard Lyon 1 , Lyon, France
- Service de Médecine Interne, Hôpital de la Croix-Rousse, Hospices Civils de Lyon , Lyon, France
| | - Etienne Merlin
- Department of Pediatrics, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Agnès Duquesne
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
- Pediatric Nephrology, Rheumatology, Dermatology Department, National Referee Centre for Rheumatic and Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | - Gilles Grateau
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
- Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France
| | - Léa Savey
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
- Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France
| | - Alexandre Thibault Jacques Maria
- Internal Medicine and Onco-Immunology (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University , Montpellier, France
| | - Anne Pagnier
- Centre Hospitalier Universitaire Grenoble Alpes, Immunologie Clinique, Immuno-Hémato-Oncologie (IHO), Hôpital Couple-Enfant , Grenoble, France
| | - Solène Poutrel
- Service de Médecine Interne, Hospices Civils de Lyon, Edouard Herriot Hospital , Lyon, France
| | - Olivier Lambotte
- Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Universitaire Paris Saclay, Hôpital Bicêtre , Le Kremlin-Bicêtre, France
- Université Paris Saclay, Inserm UMR, 1184, CEA , Le Kremlin-Bicêtre, France
| | - Coralie Mallebranche
- Université d'Angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France
- Centre Hospitalier Universitaire d'Angers, Pediatric Immuno-Hemato-Oncology Unit, France
| | - Samuel Ardois
- Médecine Interne et Immunologie Clinique , Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Olivier Richer
- Paediatric, Rheumatology and Paediatric Internal Medicine, Reference Center for Rheumatic, Autoimmune and Systemic Diseases in Children (RAISE), Children's Hospital , Bordeaux, France
| | - Irène Lemelle
- Department of Pediatric Onco-hematology, Children Hospital, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France
| | - Frédéric Rieux-Laucat
- Université Paris Cité, Institut Imagine, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Inserm UMR 1163 , Paris, France
| | - Brigitte Bader-Meunier
- Université Paris Cité, Institut Imagine, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Inserm UMR 1163 , Paris, France
- Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Zahir Amoura
- Assistance Publique-Hôpitaux de Paris (AP-HP)-Sorbonne Université, Hopital Pitié-Salpétrière, Institut E3M, Service de Médecine Interne 2, Centre National de Référence Lupus et Syndrome des Anticorps Antiphospholipides, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Paris, France
| | - Isabelle Melki
- Paediatric, Rheumatology and Paediatric Internal Medicine, Reference Center for Rheumatic, Autoimmune and Systemic Diseases in Children (RAISE), Children's Hospital , Bordeaux, France
- General Pediatrics, Infectious Disease and Internal Medicine Department, Hôpital Robert Debre, Assistance Publique-Hôpitaux de Paris (AP-HP), Reference Center for Rheumatic, AutoImmune and Systemic Diseases in Children (RAISE), Paris, France
- Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute , Paris, France
| | - Laurence Cuisset
- Université Paris Cité, Service de Médecine Génomique des Maladies de Système et D'Organe, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris , Paris, France
| | - Isabelle Touitou
- Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France
- Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
| | - Matthias Geyer
- Institute of Structural Biology, University of Bonn , Bonn, Germany
| | - Sophie Georgin-Lavialle
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France
- Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France
| | - Bénédicte F Py
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France
| |
Collapse
|
2
|
Delplanque M, Benech N, Rolhion N, Oeuvray C, Straube M, Galbert C, Brot L, Henry T, Jamilloux Y, Savey L, Grateau G, Sokol H, Georgin-Lavialle S. Gut microbiota alterations are associated with phenotype and genotype in familial Mediterranean fever. Rheumatology (Oxford) 2024; 63:1039-1048. [PMID: 37402619 DOI: 10.1093/rheumatology/kead322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 05/23/2023] [Accepted: 06/17/2023] [Indexed: 07/06/2023] Open
Abstract
OBJECTIVE FMF is the most common monogenic autoinflammatory disease associated with MEFV mutations. Disease phenotype and response to treatment vary from one patient to another, despite similar genotype, suggesting the role of environmental factors. The objective of this study was to analyse the gut microbiota of a large cohort of FMF patients in relation to disease characteristics. METHODS The gut microbiotas of 119 FMF patients and 61 healthy controls were analysed using 16 s rRNA gene sequencing. Associations between bacterial taxa, clinical characteristics, and genotypes were evaluated using multivariable association with linear models (MaAslin2), adjusting on age, sex, genotype, presence of AA amyloidosis (n = 17), hepatopathy (n = 5), colchicine intake, colchicine resistance (n = 27), use of biotherapy (n = 10), CRP levels, and number of daily faeces. Bacterial network structures were also analysed. RESULTS The gut microbiotas of FMF patients differ from those of controls in having increased pro-inflammatory bacteria, such as the Enterobacter, Klebsiella and Ruminococcus gnavus group. Disease characteristics and resistance to colchicine correlated with homozygous mutations and were associated with specific microbiota alteration. Colchicine treatment was associated with the expansion of anti-inflammatory taxa such as Faecalibacterium and Roseburia, while FMF severity was associated with expansion of the Ruminococcus gnavus group and Paracoccus. Colchicine-resistant patients exhibited an alteration of the bacterial network structure, with decreased intertaxa connectivity. CONCLUSION The gut microbiota of FMF patients correlates with disease characteristics and severity, with an increase in pro-inflammatory taxa in the most severe patients. This suggests a specific role for the gut microbiota in shaping FMF outcomes and response to treatment.
Collapse
Affiliation(s)
- Marion Delplanque
- Sorbonne Université, Service Médecine Interne, Centre de Référence des Maladies Autoinflammatoires et des Amyloses (CEREMAIA), APHP, Hôpital Tenon, Paris, France
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| | - Nicolas Benech
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| | - Nathalie Rolhion
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| | - Cyriane Oeuvray
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| | - Marjolène Straube
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| | - Chloé Galbert
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| | - Loic Brot
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| | - Thomas Henry
- CIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, University Lyon, Lyon, Rhônes, France
| | - Yvan Jamilloux
- CIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, University Lyon, Lyon, Rhônes, France
| | - Léa Savey
- Sorbonne Université, Service Médecine Interne, Centre de Référence des Maladies Autoinflammatoires et des Amyloses (CEREMAIA), APHP, Hôpital Tenon, Paris, France
| | - Gilles Grateau
- Sorbonne Université, Service Médecine Interne, Centre de Référence des Maladies Autoinflammatoires et des Amyloses (CEREMAIA), APHP, Hôpital Tenon, Paris, France
| | - Harry Sokol
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
- INRAE, UMR1319 Micalis & AgroParisTech, Jouy en Josas, Yvelines, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, Service Médecine Interne, Centre de Référence des Maladies Autoinflammatoires et des Amyloses (CEREMAIA), APHP, Hôpital Tenon, Paris, France
- Gastroenterology Department, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, French Group of Faecal Microbiota Transplantation (GFTF), Paris, France
- Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France
| |
Collapse
|
3
|
Fayand A, Kerrou K, Wendum D, Grateau G, Georgin-Lavialle S. Malignant Peritoneal Mesothelioma Complicating Familial Mediterranean Fever on 18 F-FDG PET/CT. Clin Nucl Med 2024; 49:e123-e124. [PMID: 38271241 DOI: 10.1097/rlu.0000000000005041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2024]
Abstract
ABSTRACT A 77-year-old man with a personal history of familial Mediterranean fever presented with a slowly enlarging tumefaction of the left abdominal wall and persistent inflammatory syndrome despite good adherence to colchicine. 18 F-FDG PET/CT showed a hypermetabolic muscular mass of the abdominal wall along with other hypermetabolic lesions including a peritoneal mass and several subcutaneous soft tissue nodules. CT-guided needle biopsy led to the diagnosis of a muscular localization of a malignant peritoneal mesothelioma, which is an extremely rare complication of familial Mediterranean fever. Six courses of chemotherapy with carboplatin and pemetrexed allowed an almost complete response.
Collapse
Affiliation(s)
- Antoine Fayand
- From the Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'Origine Inflammatoire, Service de Médecine Interne, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
| | - Khaldoun Kerrou
- Service de Médecine Nucléaire, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
| | - Dominique Wendum
- Service d'Anatomie et Cytologie Pathologiques, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France
| | - Gilles Grateau
- From the Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'Origine Inflammatoire, Service de Médecine Interne, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
| | - Sophie Georgin-Lavialle
- From the Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'Origine Inflammatoire, Service de Médecine Interne, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
| |
Collapse
|
4
|
Bourguiba R, Terré A, Savey L, Oziol E, Hanslik T, Kahn JE, Borie R, Cez A, Buob D, Grateau G, Boffa JJ, Georgin-Lavialle S. Symptomatic SARS-CoV2 infection associated with high mortality in AA amyloidosis. Amyloid 2023:1-3. [PMID: 38126733 DOI: 10.1080/13506129.2023.2294434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 12/08/2023] [Indexed: 12/23/2023]
Affiliation(s)
- Rim Bourguiba
- Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France
- National French Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Paris, France
| | - Alexandre Terré
- Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France
- National French Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Paris, France
| | - Lea Savey
- Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France
- National French Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Paris, France
| | - Eric Oziol
- Internal Medicine Department, Béziers Hospital, Béziers, France
| | - Thomas Hanslik
- Internal Medicine Department, Ambroise Paré Hospital, APHP, Paris, France
| | - Jean-Emmanuel Kahn
- Internal Medicine Department, Ambroise Paré Hospital, APHP, Paris, France
| | - Raphael Borie
- Pneumology Department, Bichat Hospital, AP-HP, Paris, France
| | - Alexandre Cez
- Nephrology Department, Tenon hospital, AP-HP, Paris, France
| | - David Buob
- National French Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Paris, France
- Anatomopathology Department, Tenon Hospital, AP-HP, Paris, France
- Sorbonne University, Paris, France
| | - Gilles Grateau
- Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France
- National French Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Paris, France
| | - Jean-Jacques Boffa
- National French Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Paris, France
- Nephrology Department, Tenon hospital, AP-HP, Paris, France
- Sorbonne University, Paris, France
| | - Sophie Georgin-Lavialle
- Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France
- National French Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Paris, France
- Sorbonne University, Paris, France
| |
Collapse
|
5
|
Bourguiba R, Delplanque M, Savey L, Hentgen V, Grateau G, Georgin-Lavialle S. Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado et al. Ann Rheum Dis 2023; 82:e228. [PMID: 35817471 DOI: 10.1136/annrheumdis-2022-222118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 01/12/2022] [Indexed: 11/04/2022]
Affiliation(s)
- Rim Bourguiba
- Internal Medecine, Hopital Tenon, Paris, Île-de-France, France
- Service de médecine interne, Hopital Tenon, Paris, France
- UMR_S 933, Sorbonne Universités, UPMC Univ Paris 06, Paris, Île-de-France, France
| | - Marion Delplanque
- Internal Medecine, Hopital Tenon, Paris, Île-de-France, France
- Service de médecine interne, Hopital Tenon, Paris, France
- UMR_S 933, Sorbonne Universités, UPMC Univ Paris 06, Paris, Île-de-France, France
| | - Léa Savey
- Internal Medecine, Hopital Tenon, Paris, Île-de-France, France
- Service de médecine interne, Hopital Tenon, Paris, France
- UMR_S 933, Sorbonne Universités, UPMC Univ Paris 06, Paris, Île-de-France, France
| | - Veronique Hentgen
- CeReMAI-Departement of pediatrics, Hôpital Mignot, Le Chesnay, France
| | - Gilles Grateau
- Internal Medecine, Hopital Tenon, Paris, Île-de-France, France
- Service de médecine interne, Hopital Tenon, Paris, France
- UMR_S 933, Sorbonne Universités, UPMC Univ Paris 06, Paris, Île-de-France, France
| | - Sophie Georgin-Lavialle
- Internal Medecine, Hopital Tenon, Paris, Île-de-France, France
- Service de médecine interne, Hopital Tenon, Paris, France
- UMR_S 933, Sorbonne Universités, UPMC Univ Paris 06, Paris, Île-de-France, France
- Tenon Hospital, Internal Medicine, AP-HP, Paris, France
| |
Collapse
|
6
|
Fayand A, Cescato M, Le Corre L, Terré A, Wacheux M, Zhu YYJ, Melet A, Moreau TRJ, Bodaghi B, Bonnet F, Bronnimann D, Cuisset L, Faria R, Grateau G, Pillet P, Mulders-Manders CM, Neven B, Quartier P, Richer O, Savey L, Truchetet ME, Py BF, Boursier G, Herbeuval JP, Georgin-Lavialle S, Rodero MP. Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype. J Allergy Clin Immunol 2023; 152:1303-1311.e1. [PMID: 37506976 DOI: 10.1016/j.jaci.2023.07.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 07/13/2023] [Accepted: 07/20/2023] [Indexed: 07/30/2023]
Abstract
BACKGROUND Cryopyrin-associated periodic syndrome (CAPS) is associated with NLRP3 pathogenic variants, mostly located in the NACHT (neuronal apoptosis inhibitor protein, MHC class 2 transcription activator, incompatibility locus protein from Podospora anserina, telomerase-associated protein) domain. Cold-induced urticarial rash is among the main clinical features. However, this study identified a series of 14 patients with pathogenic variants of the Y861 residue (p.Tyr861) of the LRR domain of NLRP3 and minimal prevalence of cold-induced urticarial rash. OBJECTIVES This study aimed to address a possible genotype/phenotype correlation for patients with CAPS and to investigate at the cellular levels the impact of the Y861C substitution (p.Tyr861Cys) on NLRP3 activation. METHODS Clinical features of 14 patients with CAPS and heterozygous substitution at position 861 in the LRR domain of NLRP3 were compared to clinical features of 48 patients with CAPS and pathogenic variants outside the LRR domain of NLRP3. IL-1β secretion by PBMCs and purified monocytes from patients and healthy donors was evaluated following LPS and monosodium urate crystal stimulation. RESULTS Patients with substitution at position 861 of NLRP3 demonstrated a higher prevalence of sensorineural hearing loss while being less prone to skin urticarial. In contrast to patients with classical CAPS, cells from patients with a pathogenic variant at position 861 required an activation signal to secrete IL-1β but produced more IL-1β during the early and late phase of secretion than cells from healthy donors. CONCLUSIONS Pathogenic variants of Y861 of NLRP3 drive a boost-dependent oversecretion of IL-1β associated with an atypical CAPS phenotype.
Collapse
Affiliation(s)
- Antoine Fayand
- Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and Amyloid A Amyloidosis, Tenon Hospital, Sorbonne Université, Paris, France; Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France
| | - Margaux Cescato
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France
| | - Laurent Le Corre
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France
| | - Alexandre Terré
- Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and Amyloid A Amyloidosis, Tenon Hospital, Sorbonne Université, Paris, France; Laboratoire Mécanismes Cellulaires et Moléculaires des Désordres Hématologiques et Implications Thérapeutiques, Institut Imagine, Institut National de la Santé et de la Recherche Médicale, Université Paris Cité, Paris, France
| | - Margaux Wacheux
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France
| | - Yixiang Y J Zhu
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France
| | - Armelle Melet
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France
| | - Thomas R J Moreau
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France; Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Bahram Bodaghi
- Department of Ophthalmology, Instituts Hospitalo-Universitaires FOReSIGHT, Pitié-Salpêtrière Hospital, Assistance Publique-Hȏpitaux de Paris, Sorbonne Université, Paris, France
| | - Fabrice Bonnet
- Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Didier Bronnimann
- Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Laurence Cuisset
- Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France
| | - Raquel Faria
- Unidade de Imunologia Clínica, Centro Hospitalar Universitário do Porto, Porto, Portugal; Unit for Multidisciplinary Research in Biomedicine, School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal; Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal
| | - Gilles Grateau
- Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and Amyloid A Amyloidosis, Tenon Hospital, Sorbonne Université, Paris, France
| | - Pascal Pillet
- Service de Pédiatrie et Rhumatologie Pédiatrique, Hôpital Pellegrin-Enfants, Bordeaux, France
| | - Catharina M Mulders-Manders
- Department of Internal Medicine, Radboud Expertise Center for Immunodeficiency and Autoinflammation, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Benedicte Neven
- Pediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, Université Paris Cité, Paris, France
| | - Pierre Quartier
- Pediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, Université Paris Cité, Paris, France; RAISE Reference Centre for Rare Diseases, Paris, France
| | - Olivier Richer
- Service de Pédiatrie et Rhumatologie Pédiatrique, Hôpital Pellegrin-Enfants, Bordeaux, France
| | - Léa Savey
- Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and Amyloid A Amyloidosis, Tenon Hospital, Sorbonne Université, Paris, France
| | - Marie-Elise Truchetet
- Department of Rheumatology, Hôpital Pellegrin, Bordeaux, France; Unite de Mixte Recherche 5164 ImmunoConcept, Bordeaux University Hospital, Bordeaux University, Bordeaux, France
| | - Bénédicte F Py
- Centre International de Recherche en Infectiologie, Université Lyon, Lyon, France; U1111, Institut National de la Santé et de la Recherche Médicale, Université Claude Bernard Lyon 1, Lyon, France; Unite de Mixte Recherche 5308, Centre National de la Recherche Scientifique, École Normale Supérieure de Lyon, Lyon, France
| | - Guilaine Boursier
- Laboratoire de Génétique des Maladies Rares et Autoinflammatoires, Service de Génétique Moléculaire et Cytogénomique, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Centre Hospitalier Universitaire Montpellier, Université de Montpellier, Montpellier, France
| | - Jean-Philippe Herbeuval
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France
| | - Sophie Georgin-Lavialle
- Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and Amyloid A Amyloidosis, Tenon Hospital, Sorbonne Université, Paris, France.
| | - Mathieu P Rodero
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique, Université Paris Cité, Paris, France.
| |
Collapse
|
7
|
Georgin-Lavialle S, Savey L, Cuisset L, Boursier G, Boffa JJ, Delplanque M, Bourguiba R, Monfort JB, Touitou I, Grateau G, Kone-Paut I, Hentgen V. French protocol for the diagnosis and management of familial Mediterranean fever. Rev Med Interne 2023; 44:602-616. [PMID: 37903671 DOI: 10.1016/j.revmed.2023.10.441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2023] [Accepted: 10/08/2023] [Indexed: 11/01/2023]
Abstract
Familial Mediterranean fever is the most common monogenic auto-inflammatory disease in the world. It mainly affects people originating from the Mediterranean region. The mutated gene is MEFV, which codes for pyrin. Transmission is autosomal recessive. Patients present with recurrent attacks of fever since childhood associated with abdominal and/or thoracic pain lasting an average of 2-3days and a biological inflammatory syndrome. Other symptoms include arthralgia or arthritis in large joints such as the knees and ankles, myalgia in the lower limbs and pseudo-erysipelas in the ankles. The most serious complication is inflammatory amyloidosis, which can lead to kidney failure. Treatment is based on colchicine, which helps to prevent flares and the onset of renal amyloidosis. This paper proposes national guidelines for the diagnosis, management and follow-up of familial Mediterranean fever in France, where we estimate there are between 5000 and 10,000 patients with the disease at all stages of life. The diagnosis is suspected on the basis of clinical and anamnestic factors and confirmed by genetic analysis. These guidelines also suggest a "treat-to-target" approach to disease management, particularly in case of suspected colchicine resistance - a very rare situation that should remain a diagnosis of elimination, especially after colchicine compliance has been verified. Two special situations are also addressed in these guidelines: kidney failure and pregnancy.
Collapse
Affiliation(s)
- S Georgin-Lavialle
- Internal Medicine, Sorbonne University, Tenon Hospital, Paris, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France.
| | - L Savey
- Internal Medicine, Sorbonne University, Tenon Hospital, Paris, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - L Cuisset
- Genetics, Cochin Hospital, Paris, France
| | - G Boursier
- Genetics, Montpellier University, Montpellier, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - J-J Boffa
- Nephrology, Tenon Hospital, Paris, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - M Delplanque
- Internal Medicine, Sorbonne University, Tenon Hospital, Paris, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - R Bourguiba
- Internal Medicine, Sorbonne University, Tenon Hospital, Paris, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - J-B Monfort
- Dermatology, Tenon Hospital, Paris, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - I Touitou
- Genetics, Montpellier University, Montpellier, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - G Grateau
- Internal Medicine, Sorbonne University, Tenon Hospital, Paris, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - I Kone-Paut
- Rhumatopediatry, Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| | - V Hentgen
- Paediatric Rheumatology, Versailles Hospital, Versailles, France; CEREMAIA: French National Reference Center for Auto-inflammatory Diseases and AA Amyloidosis, Paris, France
| |
Collapse
|
8
|
Collet A, Attias P, Lacou M, Fieschi C, Moktefi A, Sannier A, Grateau G, Buob D, Georgin-Lavialle S. AA-type amyloidosis associated with lymphoma: a study of 19 cases including 5 new French cases and a systematic literature review. Leuk Lymphoma 2023; 64:1857-1863. [PMID: 37493601 DOI: 10.1080/10428194.2023.2239971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 07/18/2023] [Indexed: 07/27/2023]
Affiliation(s)
- Aurore Collet
- Sorbonne Université, GRC 28 SU, AP-HP, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris, France
| | - Philippe Attias
- Hôpital privé Nord Parisien, Service de néphrologie, Paris, France
| | - Mathieu Lacou
- CHU de Nantes, service de médecine interne, Nantes, France
| | - Claire Fieschi
- Clinical Immunology Department, Hôpital Saint Louis, Assistance Publique Hôpitaux de Paris (APHP) Université Paris Diderot, Paris, France
| | - Anissa Moktefi
- APHP (Assistance Publique-Hôpitaux de Paris), Département de Pathologie, Hôpitaux Universitaires Henri Mondor, Univ Paris Est Créteil, Créteil, France
| | - Aurélie Sannier
- Département de Pathologie, Université de Paris, INSERM U1148, Hôpital Bichat, Paris, France
| | - Gilles Grateau
- Sorbonne Université, GRC 28 SU, AP-HP, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris, France
| | - David Buob
- AP-HP, Hôpital Tenon, Anatomie et cytologie pathologiques, Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, GRC 28 SU, AP-HP, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris, France
| |
Collapse
|
9
|
Sbeih N, Bourguiba R, Hoyeau-Idrissi N, Launay JM, Callebert J, Canioni D, Sokol H, Hentgen V, Grateau G, Hermine O, Georgin-Lavialle S. Histamine elevation in familial Mediterranean fever: A study from the Juvenile Inflammatory Rheumatism cohort. Eur J Intern Med 2023; 116:89-95. [PMID: 37349205 DOI: 10.1016/j.ejim.2023.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 05/10/2023] [Accepted: 06/09/2023] [Indexed: 06/24/2023]
Abstract
BACKGROUND Familial Mediterranean Fever (FMF) is the most frequent monogenic autoinflammatory disease (AID). Some patients have persistent symptoms despite colchicine intake. Mast cells (MC) are innate immune cells involved in inflammatory conditions including AID. Their activation is responsible for various symptoms such as abdominal pain, bloating and pruritus. OBJECTIVE Our objective was to evaluate features of a systemic MC activation in FMF adult patients. METHODS FMF adult patients prospectively filled a MC activation survey and usual MC mediators (tryptase and histamine in whole blood, plasma and urine) were measured. They were compared with a healthy control group (HC) and a systemic mastocytosis (SM) group. When digestive biopsies were realized during follow-up, MC infiltration in digestive mucosa was analyzed in FMF, in comparison with SM, Crohn disease (CD) and normal biopsies. RESULTS Forty-four FMF patients, 44 HC and 44 SM patients were included. Thirty-one (70%) FMF patients had symptoms of mast cell activation, versus 14 (32%) in the HC group (p = 0.0006). Thirty (68%) FMF patients had at least one elevated MC mediator: mainly whole blood histamine, in 19 (43%) and urinary histamine, in 14 (32%), which were significantly higher than in HC subjects. MC infiltration was comparable in FMF digestive biopsies, biopsies of CD and normal biopsies but was lower than in SM biopsies. CONCLUSION FMF patients show frequent symptoms of MC activation and an increase of blood or urinary histamine never described before in this disease. This suggests an implication of MC and possibly basophils in FMF pathophysiology.
Collapse
Affiliation(s)
- Nabiha Sbeih
- Department of Internal Medicine, National Reference Centre for Auto-inflammatory Diseases and inflammatory Amyloidosis (CEREMAIA), Tenon Hospital, AP-HP, Paris, France; Sorbonne Université, Inserm U938, Paris, France; Laboratory of Molecular mechanisms of Hematological disorders and therapeutic implications, INSERM U1163 and CNRS ERL 8254, Fondation Imagine, Paris, France
| | - Rim Bourguiba
- Department of Internal Medicine, National Reference Centre for Auto-inflammatory Diseases and inflammatory Amyloidosis (CEREMAIA), Tenon Hospital, AP-HP, Paris, France; Sorbonne Université, Inserm U938, Paris, France
| | | | - Jean-Marie Launay
- Service de Biochimie et Biologie Moléculaire, INSERM U942, Hôpital Lariboisière et Université Paris Cité, AP-HP, Paris, France
| | - Jacques Callebert
- Service de Biochimie et Biologie Moléculaire, INSERM U942, Hôpital Lariboisière et Université Paris Cité, AP-HP, Paris, France
| | - Danielle Canioni
- Laboratoire d'Anatomie-Pathologie, Hôpital Necker-Enfants Malades, AP-HP et Université Paris Cité, Paris, France
| | - Harry Sokol
- Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, AP-HP, Paris, France et Sorbonne Université, Equipe AVENIR, Laboratoire INSERM U938, Paris, France; Equipe Interactions des bactéries commensales et probiotiques avec l'hôte, MICALIS, INRA, Jouy en Josas, France
| | - Véronique Hentgen
- Department of General Pediatrics, André Mignot Hospital, National Reference Centre for Auto-inflammatory Diseases and inflammatory Amyloidosis (CEREMAIA), Versailles, France
| | - Gilles Grateau
- Department of Internal Medicine, National Reference Centre for Auto-inflammatory Diseases and inflammatory Amyloidosis (CEREMAIA), Tenon Hospital, AP-HP, Paris, France
| | - Olivier Hermine
- Centre de Référence des Mastocytoses, Service d'Hématologie adulte, Université Paris Cité, Hôpital Necker-Enfants malades, AP-HP, Paris, France; Laboratory of Molecular mechanisms of Hematological disorders and therapeutic implications, INSERM U1163 and CNRS ERL 8254, Fondation Imagine, Paris, France
| | - Sophie Georgin-Lavialle
- Department of Internal Medicine, National Reference Centre for Auto-inflammatory Diseases and inflammatory Amyloidosis (CEREMAIA), Tenon Hospital, AP-HP, Paris, France; Sorbonne Université, Inserm U938, Paris, France.
| |
Collapse
|
10
|
Soria A, Amsler E, Garel B, Moguelet P, Tieulié N, Cordoliani F, Guichard I, Mahé A, Grateau G, Boursier G, Georgin-Lavialle S. Systemic inflammatory trunk recurrent acute macular eruption (SITRAME): A new auto-inflammatory syndrome in adult? J Eur Acad Dermatol Venereol 2023; 37:e538-e542. [PMID: 36426626 DOI: 10.1111/jdv.18771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 11/21/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Angèle Soria
- Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, DMU3ID, APHP, Paris, France.,Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France
| | - Emmanuelle Amsler
- Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, DMU3ID, APHP, Paris, France
| | - Bethsabée Garel
- Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, DMU3ID, APHP, Paris, France
| | | | - Nathalie Tieulié
- Service de Rhumatologie, CHU Nice, Hôpital Pasteur, Nice, France
| | | | | | - Antoine Mahé
- Service de Dermatologie, Hôpital de Colmar, Colmar, France
| | - Gilles Grateau
- Sorbonne Université, Service de médecine interne, Hôpital Tenon, DMU 3ID, APHP, Paris, France.,Centre National de Référence des Maladies Auto-Inflammatoires et des Amyloses D'Origine Inflammatoire (CEREMAIA), Paris, France
| | - Guilaine Boursier
- Centre National de Référence des Maladies Auto-Inflammatoires et des Amyloses D'Origine Inflammatoire (CEREMAIA), Montpellier, France.,Laboratoire de Génétique des Maladies rares et autoinflammatoires, Service de Génétique moléculaire et cytogénomique, CHU Montpellier, Univ Montpellier, Montpellier, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, Service de médecine interne, Hôpital Tenon, DMU 3ID, APHP, Paris, France.,Centre National de Référence des Maladies Auto-Inflammatoires et des Amyloses D'Origine Inflammatoire (CEREMAIA), Paris, France.,INSERM U938, CRSA, Paris, France
| |
Collapse
|
11
|
Terré A, Savey L, Buob D, Grateau G, Georgin-Lavialle S. Identification of factors for persistence of AA amyloidosis in patients with Familial Mediterranean Fever. Eur J Intern Med 2023; 108:128-130. [PMID: 36229286 DOI: 10.1016/j.ejim.2022.09.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 09/13/2022] [Accepted: 09/15/2022] [Indexed: 02/07/2023]
Affiliation(s)
- Alexandre Terré
- Department of Internal Medicine, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'origine Inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, 20, Rue de la Chine GRC-28, Paris 75020, France; Institut Imagine, INSERM U1163, CNRS ERL 8254, Laboratoire d'Excellence GR-Ex, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France
| | - Léa Savey
- Department of Internal Medicine, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'origine Inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, 20, Rue de la Chine GRC-28, Paris 75020, France
| | - David Buob
- Department of Pathology, Sorbonne University, AP-HP, Tenon Hospital, Paris, France
| | - Gilles Grateau
- Department of Internal Medicine, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'origine Inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, 20, Rue de la Chine GRC-28, Paris 75020, France
| | - Sophie Georgin-Lavialle
- Department of Internal Medicine, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'origine Inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, 20, Rue de la Chine GRC-28, Paris 75020, France.
| |
Collapse
|
12
|
Georgin-Lavialle S, Savey L, Buob D, Bastard JP, Fellahi S, Karras A, Boffa JJ, Grateau G, Audard V, Bridoux F, Damade R, Deshayes S, Giurgea I, Granel B, Hachulla E, Hot A, Jaccard A, Knebelmann B, Marciano S, Pelcot F, Sarrabay G, Boursier G, Sellam J, Terre A, Bourguiba R. French practical guidelines for the diagnosis and management of AA amyloidosis. Rev Med Interne 2023; 44:62-71. [PMID: 36759076 DOI: 10.1016/j.revmed.2022.12.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Accepted: 12/11/2022] [Indexed: 01/25/2023]
Abstract
AA amyloidosis is secondary to the deposit of excess insoluble Serum Amyloid A (SAA) protein fibrils. AA amyloidosis complicates chronic inflammatory diseases, especially chronic inflammatory rheumatisms such as rheumatoid arthritis and spondyloarthritis; chronic infections such as tuberculosis, bronchectasia, chronic inflammatory bowel diseases such as Crohn's disease; and auto-inflammatory diseases including familial Mediterranean fever. This work consists of the French guidelines for the diagnosis workup and treatment of AA amyloidosis. We estimate in France between 500 and 700 cases in the whole French population, affecting both men and women. The most frequent organ impaired is kidney which usually manifests by oedemas of the lower extremities, proteinuria, and/or renal failure. Patients are usually tired and can display digestive features anf thyroid goiter. The diagnosis of AA amyloidosis is based on detection of amyloid deposits on a biopsy using Congo Red staining with a characteristic green birefringence in polarized light. Immunohistochemical analysis with an antibody directed against Serum Amyloid A protein is essential to confirm the diagnosis of AA amyloidosis. Peripheral inflammatory biomarkers can be measured such as C Reactive protein and SAA. We propose an algorithm to guide the etiological diagnosis of AA amyloidosis. The treatement relies on the etiologic treatment of the undelying chronic inflammatory disease to decrease and/or normalize Serum Amyloid A protein concentration in order to stabilize amyloidosis. In case of renal failure, dialysis or even a kidney transplant can be porposed. Nowadays, there is currently no specific treatment for AA amyloidosis deposits which constitutes a therapeutic challenge for the future.
Collapse
Affiliation(s)
- S Georgin-Lavialle
- Sorbonne University, Internal medicine department, Tenon hospital, National reference center for autoinflamamtory diseases and AA amylodiosis (CEREMAIA), 4 rue de la Chine, 75020 Paris, France.
| | - L Savey
- Sorbonne University, Internal medicine department, Tenon hospital, National reference center for autoinflamamtory diseases and AA amylodiosis (CEREMAIA), 4 rue de la Chine, 75020 Paris, France
| | - D Buob
- Sorbonne University, department of pathology, Tenon hospital, Paris, France
| | - J-P Bastard
- Biochemistry department, Henri-Mondor hospital, Créteil, France
| | - S Fellahi
- Sorbonne University, Nephrology department, Tenon hospital, Paris, France
| | - A Karras
- Paris centre university, Nephrology department, Georges Pompidou European hospital, Paris, France
| | - J-J Boffa
- Sorbonne University, Nephrology department, Tenon hospital, Paris, France
| | - G Grateau
- Sorbonne University, Internal medicine department, Tenon hospital, National reference center for autoinflamamtory diseases and AA amylodiosis (CEREMAIA), 4 rue de la Chine, 75020 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Delplanque M, Fayand A, Boursier G, Grateau G, Savey L, Georgin-Lavialle S. Diagnostic and therapeutic algorithms for monogenic autoinflammatory diseases presenting with recurrent fevers among adults. Rheumatology (Oxford) 2022:6964376. [PMID: 36575989 DOI: 10.1093/rheumatology/keac712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 11/30/2022] [Accepted: 12/09/2022] [Indexed: 12/29/2022] Open
Abstract
Autoinflammatory diseases (AIDs) are defined as disorders of innate immunity. They were initially defined in contrast to autoimmune diseases because of the lack of involvement of the adaptive immune system and circulating autoantibodies. The four monogenic AIDs first described are called the "historical" AIDs and include: Familial Mediterranean Fever (associated with MEFV mutations), cryopyrinopathies (associated with NLRP3 mutations), Tumor Necrosis Factor Receptor-associated Periodic Syndrome (associated with TNFRSF1A mutations) and Mevalonate Kinase Deficiency (associated with MVK mutations). In the last 10 years, >50 new monogenic AIDs have been discovered due to genetic advances. The most important discovery for adult patients is VEXAS syndrome associated with somatic UBA1 mutations leading to an autoinflammatory disease affecting mostly elderly men. Diagnosis of monogenic AIDs is based on personal and family history and detailed analysis of symptoms associated with febrile attacks, in the context of elevated peripheral inflammatory markers. This review proposes a practical approach of the diagnosis of the main monogenic AIDs among adult patients to guide the clinician.
Collapse
Affiliation(s)
- Marion Delplanque
- Sorbonne University, AP-HP, Tenon hospital, internal medicine department, 4 rue de la Chine, Paris, 75020, France.,National reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
| | - Antoine Fayand
- Sorbonne University, AP-HP, Tenon hospital, internal medicine department, 4 rue de la Chine, Paris, 75020, France.,National reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
| | - Guilaine Boursier
- Department of molecular Genetics and cytogenomics, Rare and Auto Inflammatory Diseases Unit, CHU Montpellier, University of Montpellier, Montpellier, France.,National reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
| | - Gilles Grateau
- Sorbonne University, AP-HP, Tenon hospital, internal medicine department, 4 rue de la Chine, Paris, 75020, France.,National reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
| | - Léa Savey
- Sorbonne University, AP-HP, Tenon hospital, internal medicine department, 4 rue de la Chine, Paris, 75020, France.,National reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
| | - Sophie Georgin-Lavialle
- Sorbonne University, AP-HP, Tenon hospital, internal medicine department, 4 rue de la Chine, Paris, 75020, France.,National reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
| |
Collapse
|
14
|
Assrawi E, Louvrier C, El Khouri E, Delaleu J, Copin B, Dastot-Le Moal F, Piterboth W, Legendre M, Karabina SA, Grateau G, Amselem S, Giurgea I. Mosaic variants in TNFRSF1A: an emerging cause of tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2022; 62:473-479. [PMID: 35640127 DOI: 10.1093/rheumatology/keac274] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 04/24/2022] [Accepted: 04/24/2022] [Indexed: 12/27/2022] Open
Abstract
OBJECTIVE To identify the molecular basis of a systemic autoinflammatory disorder (SAID) evocative of TNF receptor-associated periodic syndrome (TRAPS). METHODS (i) Deep next generation sequencing (NGS) through a SAID gene panel; (ii) variant allele distribution in peripheral blood subpopulations; (iii) in silico analyses of mosaic variants using TNF receptor superfamily 1A (TNFRSF1A) crystal structure; (iv) review of the very rare TNFRSF1A mosaic variants reported previously. RESULTS In a 36-year-old man suffering from recurrent fever for 12 years, high-depth NGS revealed a TNFRSF1A mosaic variant, c.176G>A p.(Cys59Tyr), which Sanger sequencing failed to detect. This mosaic variant displayed a variant allele fraction of 14% in whole blood; it affects both myeloid and lymphoid lineages. p.(Cys59Tyr), a recurrent germline pathogenic variant, affects a crucial cysteine located in the first cysteine-rich domain (CRD1) and involved in a disulphide bridge. Introduction of a tyrosine at this position is expected to disrupt the CRD1 structure. Review of the three previously reported TNFRSF1A mosaic variants revealed that they are all located in a small region of CRD2 and that germinal cells can be affected. CONCLUSION This study expands the localization of TNFRSF1A mosaic variants to the CRD1 domain. Noticeably, residues involved in germline TNFRSF1A mutational hot spots can also be involved in post-zygotic mutational events. Including our study, only four patients have been thus far reported with TNFRSF1A mosaicism, highlighting the need for a high-depth NGS-based approach to avoid the misdiagnosis of TRAPS. Genetic counselling has to consider the potential occurrence of TNFRSF1A mosaic variants in germinal cells.
Collapse
Affiliation(s)
- Eman Assrawi
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique
| | - Camille Louvrier
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique.,Unité Fonctionnelle de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau
| | - Elma El Khouri
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique
| | - Jérémie Delaleu
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique
| | - Bruno Copin
- Unité Fonctionnelle de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau
| | - Florence Dastot-Le Moal
- Unité Fonctionnelle de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau
| | - William Piterboth
- Unité Fonctionnelle de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau
| | - Marie Legendre
- Unité Fonctionnelle de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau
| | - Sonia A Karabina
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique
| | - Gilles Grateau
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique.,Service de Médecine Interne, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France
| | - Serge Amselem
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique.,Unité Fonctionnelle de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau
| | - Irina Giurgea
- Sorbonne Université, INSERM, Maladies Génétiques d'Expression Pédiatrique.,Unité Fonctionnelle de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau
| |
Collapse
|
15
|
Rodrigues F, Cuisset L, Cador-Rousseau B, Giurgea I, Neven B, Buob D, Quartier P, Hachulla E, Lequerré T, Cam G, Boursier G, Hervieu V, Grateau G, Georgin-Lavialle S. AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. Rheumatology (Oxford) 2022; 61:4827-4834. [PMID: 35262642 DOI: 10.1093/rheumatology/keac145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 02/22/2022] [Indexed: 01/11/2023] Open
Abstract
OBJECTIVE Cryopyrin-associated periodic syndrome (CAPS) is a rare but treatable inherited autoinflammatory condition including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and chronic infantile neurologic cutaneous articular syndrome (CINCA). Our objective was to describe the main features of CAPS AA amyloidosis (AA-CAPS) associated and the efficacy of IL-1 inhibitors in this indication. METHODS Retrospective study in France associated with a systematic literature review. RESULTS Eighty-six patients were identified: 23 new French cases and 63 from the literature, with a median age at amyloidosis diagnosis of 39 years old. CAPS subtypes were MWS (n = 62), FCAS (n = 9), frontier forms between MWS and FCAS (n = 12) and between CINCA and MWS (n = 3). NLRP3 had been sequenced in 60 patients (70%) and the most frequent mutation was R260W (60%). Three AA-CAPS patients displayed somatic NLRP3 mutations. Death occurred in 35 patients (41%), none of whom having ever received IL-1 inhibitors. Twenty-eight patients (33%) received IL-1 inhibitors, with a >50% decrease in proteinuria in 89% of cases. CONCLUSION AA amyloidosis can occur in nearly all CAPS subtypes. IL-1 inhibitors are effective, underlining the necessity of an early diagnosis of CAPS in order to start this treatment as soon as possible among AA-CAPS patients.
Collapse
Affiliation(s)
- François Rodrigues
- Internal Medicine Department, Sorbonne Université, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris
| | - Laurence Cuisset
- Department of Genetics, Cochin Hospital, Université de Paris, Paris
| | | | - Irina Giurgea
- Département de Génétique Médicale, Sorbonne Université, INSERM Childhood Genetic Diseases, AP-HP. Hôpital Trousseau
| | - Benedicte Neven
- Department of Rheumatologic Pediatry, Necker Hospital, Université de Paris
| | - David Buob
- Department of Pathology, Sorbonne Université, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris
| | - Pierre Quartier
- Department of Rheumatologic Pediatry, Necker Hospital, Université de Paris
| | - Eric Hachulla
- Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille
| | - Thierry Lequerré
- Department of Rheumatology & CIC-CRB1404, INSERM, U1234, Normandie University, Rouen University Hospital, Rouen
| | - Gérard Cam
- Service de néphrologie, Centre hospitalier de Saint-Malo, Saint-Malo
| | - Guilaine Boursier
- Laboratory of Rare and Autoinflammatory Genetic Diseases and Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), CHU Montpellier, University of Montpellier, Montpellier
| | | | - Gilles Grateau
- Internal Medicine Department, Sorbonne Université, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris.,Groupe de recherche clinique amylose AA (GRC AA SU), Sorbonne Université, Paris, France
| | - Sophie Georgin-Lavialle
- Internal Medicine Department, Sorbonne Université, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris.,Groupe de recherche clinique amylose AA (GRC AA SU), Sorbonne Université, Paris, France
| |
Collapse
|
16
|
Abbara S, Monfort JB, Savey L, Moguelet P, Saadoun D, Bachmeyer C, Fain O, Terrier B, Amoura Z, Mathian A, Gilardin L, Buob D, Job-Deslandre C, Dufour JF, Sberro-Soussan R, Grateau G, Georgin-Lavialle S. Vasculitis and familial Mediterranean fever: Description of 22 French adults from the juvenile inflammatory rheumatism cohort. Front Med (Lausanne) 2022; 9:1000167. [PMID: 36388918 PMCID: PMC9649929 DOI: 10.3389/fmed.2022.1000167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 10/11/2022] [Indexed: 01/27/2023] Open
Abstract
Objective The frequency of vasculitis may be increased in patients with Familial Mediterranean Fever (FMF), according to several studies. Our aim was to assess the characteristics of French adult patients with both diseases. Methods Patients with vasculitis were selected from patients followed for FMF in the French JIR-cohort. Results Twenty-two patients were included [polyarteritis nodosa (PAN) n = 10, IgA vasculitis n = 8, unclassified vasculitis n = 2, granulomatosis with polyangiitis n = 1, and microscopic polyangiitis n = 1]. Pathogenic mutations in exon 10 were found in all 21 patients (96%) for which MEFV testing results were available, and 18 (82%) had two pathogenic mutations. Histology showed vasculitis in 59% of patients. Most patients with FMF-associated PAN were HBV-negative and had an inactive FMF before PAN onset, and 40% had a peri-renal or central nervous system bleeding. Most patients with FMF-associated IgA vasculitis had an active FMF before vasculitis onset, and 25% had digestive bleeding. Both patients with unclassified vasculitis had ischemic and/or hemorrhagic complications. Conclusion This study confirms the predominance of PAN and IgA vasculitis in patients with FMF and the high frequency of bleeding in FMF-associated PAN. FMF should be considered in case of persistent symptoms and/or inflammatory syndrome despite vasculitis treatment in Mediterranean patients.
Collapse
Affiliation(s)
- Salam Abbara
- Département de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d’Origine Inflammatoire (CEREMAIA), Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
| | - Jean-Benoit Monfort
- Département de Dermatologie, Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
| | - Léa Savey
- Département de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d’Origine Inflammatoire (CEREMAIA), Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
| | - Philippe Moguelet
- Département d’Anatomo-Pathologie, Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
| | - David Saadoun
- Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose Inflammatoire, INSERM UMR_S 959, Immunologie-Immunopathologie-Immunotherapie, i3 and Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biothérapie i2B, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, AP-HP, Paris, France
| | - Claude Bachmeyer
- Département de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d’Origine Inflammatoire (CEREMAIA), Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
| | - Olivier Fain
- Service de Médecine Interne, Hôpital Saint-Antoine, Sorbonne Université, APHP, Paris, France
| | - Benjamin Terrier
- Service de Médecine Interne, Centre de Référence Maladies Systémiques et Autoimmunes Rares d’Ile de France, Hôpital Cochin, Université Paris Cité, AP-HP, Paris, France
| | - Zahir Amoura
- Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Groupement Hospitalier Pitié–Salpêtrière, Sorbonne Université, AP-HP, Paris, France
| | - Alexis Mathian
- Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Groupement Hospitalier Pitié–Salpêtrière, Sorbonne Université, AP-HP, Paris, France
| | - Laurent Gilardin
- Département de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, AP-HP, Paris, France
| | - David Buob
- Département d’Anatomo-Pathologie, Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
| | - Chantal Job-Deslandre
- Service de Pédiatrie, Immunologie, Hématologie et Rhumatologie, Centre de Référence pour les Rhumatismes Inflammatoires et les Maladies Auto-Immunes Systémique Rare de l’Enfant (RAISE), Hôpital Necker-Enfants Malades, AP-HP, Université Paris Cité, Paris, France
| | - Jean-François Dufour
- Service Médecine Interne, Hôpital Nord-Ouest, Centre Hospitalier Villefranche sur Saône, Gleize, France
| | - Rebecca Sberro-Soussan
- Service de Transplantation Rénale Adulte, Hôpital Necker-Enfants Malades, AP-HP, Université Paris Cité, Paris, France
| | - Gilles Grateau
- Département de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d’Origine Inflammatoire (CEREMAIA), Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
| | - Sophie Georgin-Lavialle
- Département de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d’Origine Inflammatoire (CEREMAIA), Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France
- INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
- *Correspondence: Sophie Georgin-Lavialle,
| |
Collapse
|
17
|
Rouet A, Deshayes S, Savey L, Grateau G, Georgin-Lavialle S. Quality of life assessment by SF-36 in elderly patients with familial Mediterranean fever: a comparative cross-sectional study from the Juvenile Inflammatory Rheumatism cohort. Clin Exp Rheumatol 2022; 40:1603-1604. [DOI: 10.55563/clinexprheumatol/4ft7y1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 05/12/2022] [Indexed: 11/13/2022]
Affiliation(s)
- Audrey Rouet
- Sorbonne Université, GRAASU GRC, Service de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Tenon, AP-HP, Paris, France
| | - Samuel Deshayes
- Sorbonne Université, GRAASU GRC, Service de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Tenon, AP-HP, Paris, and Service de Médecine Interne, Normandie Université, UNICAEN, UR4650 PSIR, CHU de Caen Normandie, Caen, France
| | - Léa Savey
- Sorbonne Université, GRAASU GRC, Service de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Tenon, AP-HP, Paris, France
| | - Gilles Grateau
- Sorbonne Université, GRAASU GRC, Service de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Tenon, AP-HP, Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, GRAASU GRC, Service de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoires (CEREMAIA), Hôpital Tenon, AP-HP, Paris, France.
| |
Collapse
|
18
|
Damy T, Adams D, Bridoux F, Grateau G, Planté-Bordeneuve V, Ghiron Y, Farrugia A, Pelcot F, Taieb C, Labeyrie C, Jaccard A, Georgin-Lavialle S. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid 2022; 29:165-174. [PMID: 35144512 DOI: 10.1080/13506129.2022.2035354] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
BACKGROUND Amyloidosis is a complex group of rare conditions. For patients, amyloidosis is severely debilitating: physically and psychologically. Currently, data are lacking to evaluate the medical, economic, and social burden of systemic amyloidosis. OBJECTIVE To analyse the patient burden according to the main types of systemic amyloidosis. METHODS The French Daily Impact of Amyloidosis study was an observational, cross-sectional and non-interventional study. Adults diagnosed with light chain (AL), transthyretin (ATTR), amyloid A (AA) and other rare forms of amyloidosis were eligible. Data regarding amyloidosis prevalence, diagnosis, management, and impact on everyday life were collected using a study-specific survey built by the Association Française Contre l'Amylose (AFCA) and the four French National Referral Centres for Amyloidosis. RESULTS A total of 603 patients, predominantly male (65%) with an average age of 66.8 years, including 170 AL, 224 ATTRv, 109 ATTRwt and 25 AA amyloidosis patients, completed the study-specific survey. The median delay from presentation to confirmed diagnosis was 27.4 months but varied according to amyloidosis type. Patients before diagnosis had breathlessness (49%), tingling sensation (33%), pain (28%), difficulty in walking (28%) and weight loss (22%). Amyloidosis was most frequently suspected (49%) and confirmed (57%) in local hospitals but managed in French amyloidosis referral centres (58%). Patients often reported problems with mobility, usual activities, pain/discomfort and anxiety/depression, but not with self-care. CONCLUSIONS Systemic amyloidosis severely impacts daily life. The delay to confirmed amyloidosis diagnosis needs to be reduced. Early, effective treatment is required to optimise patient benefits.
Collapse
Affiliation(s)
- Thibaud Damy
- Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Reseau amylase, Créteil, France.,Filière CARDIOGEN.,Department of Cardiology, DHU A-TVB, CHU Henri Mondor, AP-HP, INSERM U955 and UPEC, Créteil, France
| | - David Adams
- Filière FILNEMUS.,Referral Center for Familial Amyloid Polyneuropathy (NNERF), Le Kremlin Bicêtre, France.,Departement of Neurology, CHU Bicêtre, AP-HP, INSERM U 1195 and University of Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Frank Bridoux
- Referral Center for AL amyloidosis, Limoges, France.,Filière MARIH, Paris, France.,Department of Nephrology, CHRU Poitiers, Poitiers, France
| | - Gilles Grateau
- Filière FAI2R.,Department of Internal Medicine, Sorbonne University, GRC AA SU, CHU Tenon, AP-HP, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis (CEREMAIA), Paris, France
| | - Violaine Planté-Bordeneuve
- Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Reseau amylase, Créteil, France.,Department of Neurology, CHU Henri Mondor, AP-HP, INSERM U955 and UPEC, Créteil, France
| | - Yves Ghiron
- Department of Cardiology, DHU A-TVB, CHU Henri Mondor, AP-HP, INSERM U955 and UPEC, Créteil, France
| | - Agnès Farrugia
- Association Française Contre l'Amylose, Marseille, France
| | | | | | - Céline Labeyrie
- Filière FILNEMUS.,Referral Center for Familial Amyloid Polyneuropathy (NNERF), Le Kremlin Bicêtre, France.,Departement of Neurology, CHU Bicêtre, AP-HP, INSERM U 1195 and University of Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Arnaud Jaccard
- Referral Center for AL amyloidosis, Limoges, France.,Filière MARIH, Paris, France.,Department of Hematology, CHRU Limoges, Limoges, France
| | - Sophie Georgin-Lavialle
- Filière FAI2R.,Department of Internal Medicine, Sorbonne University, GRC AA SU, CHU Tenon, AP-HP, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis (CEREMAIA), Paris, France
| |
Collapse
|
19
|
Colombat M, Gaspard M, Camus M, Dalloux-Chioccioli J, Delas A, Poullot E, Moktefi A, François A, Moreau A, Gibier JB, Raynaud P, Huart A, Piedrafita A, Gilhodes J, Lairez O, Grateau G, Georgin-Lavialle S, Maisonneuve H, Moreau P, Jaccard A, Bridoux F, Plante-Bordeneuve V, Damy T, Mal H, Brousset P, Valleix S, Burlet-Schiltz O. Mass spectrometry-based proteomics in clinical practice amyloid typing: state-of-the-art from a French nationwide cohort. Haematologica 2022; 107:2983-2987. [PMID: 35924579 PMCID: PMC9713554 DOI: 10.3324/haematol.2022.281431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Indexed: 12/14/2022] Open
Affiliation(s)
- Magali Colombat
- Département d’Anatomie Pathologique, Institut Universitaire du Cancer IUCT-O, CHU Toulouse, Toulouse,M. COLOMBAT -
| | - Margot Gaspard
- Département d’Anatomie Pathologique, Institut Universitaire du Cancer IUCT-O, CHU Toulouse, Toulouse
| | - Mylène Camus
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse,Infrastructure Nationale de Protéomique, ProFI, Toulouse
| | | | - Audrey Delas
- Département d’Anatomie Pathologique, Institut Universitaire du Cancer IUCT-O, CHU Toulouse, Toulouse
| | - Elsa Poullot
- Département d’Anatomie Pathologique, Réseau Amylose, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil
| | - Anissa Moktefi
- Département d’Anatomie Pathologique, Réseau Amylose, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil,Institut Mondor de Recherche Biomédicale Université Paris Est Créteil, INSERM U955, Créteil
| | - Arnaud François
- Service d’Anatomie et Cytologie Pathologiques, CHU Rouen, Rouen
| | - Anne Moreau
- Service d’Anatomie et Cytologie Pathologiques, CHU Nantes, Nantes
| | | | - Pierre Raynaud
- Service d’Anatomie et Cytologie Pathologiques, Centre Hospitalier Maréchal Joffre, Perpignan
| | - Antoine Huart
- Service de Néphrologie Dialyse et Transplantation, CHU Toulouse, Toulouse
| | - Alexis Piedrafita
- Service de Néphrologie Dialyse et Transplantation, CHU Toulouse, Toulouse,Institut des Maladies Cardiovasculaires et Métaboliques, INSERM, UMR 1297, Université Toulouse, Toulouse
| | - Julia Gilhodes
- Service de Biostatistiques, Institut Claudius Regaud IUCT-O, Toulouse
| | | | - Gilles Grateau
- Sorbonne Université, GRC GRAASU N°28, Service de Médecine Interne, Hôpital Tenon, AP-HP, DMU3ID, CEREMAIA (Centre national de référence des maladies autoinflammatoires et amyloses AA) Paris
| | - Sophie Georgin-Lavialle
- Sorbonne Université, GRC GRAASU N°28, Service de Médecine Interne, Hôpital Tenon, AP-HP, DMU3ID, CEREMAIA (Centre national de référence des maladies autoinflammatoires et amyloses AA) Paris
| | - Hervé Maisonneuve
- Service de Médecine Interne Oncohématologie, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon
| | | | - Arnaud Jaccard
- Service d’Hématologie Clinique et Centre de Référence « Amylose AL et autres maladies à dépôt d’immunoglobulines monoclonales », CHU Limoges, Limoges
| | - Franck Bridoux
- Service de Néphrologie et Centre de Référence « Amylose AL et autres maladies à dépôt d’immunoglobulines monoclonales », CHU Poitiers, Poitiers
| | - Violaine Plante-Bordeneuve
- Institut Mondor de Recherche Biomédicale Université Paris Est Créteil, INSERM U955, Créteil,Département de Neurologie, Réseau Amylose, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil
| | - Thibaud Damy
- Service de Cardiologie, Unité Insuffisance Cardiaque et Amylose, Centre de Référence National des Amyloses Cardiaques (filière CARDIOGEN), CHU Henri Mondor, Créteil
| | - Hervé Mal
- Service de Pneumologie, Hôpital Bichat, Paris
| | - Pierre Brousset
- Département d’Anatomie Pathologique, Institut Universitaire du Cancer IUCT-O, CHU Toulouse, Toulouse
| | - Sophie Valleix
- Service de Médecine Génomique des Maladies de Système et d’Organe, APHP, Centre Université de Paris, Fédération de Génétique et de Médecine Génomique, Hôpital Cochin, Paris and ,Centre de Recherche des Cordeliers, INSERM UMR1138, Université de Paris, France
| | - Odile Burlet-Schiltz
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse,Infrastructure Nationale de Protéomique, ProFI, Toulouse
| |
Collapse
|
20
|
Elhani I, Hentgen V, Grateau G, Georgin-Lavialle S. Neurological manifestations in mevalonate kinase deficiency: A systematic review. Mol Genet Metab 2022; 136:85-93. [PMID: 35525811 DOI: 10.1016/j.ymgme.2022.04.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 04/26/2022] [Accepted: 04/26/2022] [Indexed: 11/22/2022]
Abstract
INTRODUCTION Mevalonate kinase deficiency (MKD) is a monogenic auto-inflammatory disease. Its manifestations range from partial MKD to mevalonic aciduria (MVA). All patients display a periodic fever, and MVA patients additionally exhibit severe neurological involvement. The objective of this work was to describe neurological manifestations of MKD. METHODS A systematic literature review was performed from January 1990 to January 2022. Forty-five patients from 18 case reports and five cohort studies were included in the analysis. RESULTS In cohort studies, the most-reported manifestations were headaches (41%) and fatigue (31%). Serious involvements including ataxia and developmental delay were described less than 1% of patients but 22-31% of case reports. They consistently appeared in the first years of life. Retinal dystrophy was frequently reported (31%) in case reports. Other manifestations, including uveitis, aseptic meningitis, and stroke remained rare. DISCUSSION Severe neurological manifestations are rare in MKD but are responsible for major functional disabilities. They are present at onset and never appear at follow-up of patients with mild MKD. Conversely, headaches and fatigue are frequent symptoms that should be investigated. Visual examinations should be performed on the appearance of visual symptoms. The efficacy of anti-IL-1β therapy on neurological manifestations should be further investigated.
Collapse
Affiliation(s)
- Inès Elhani
- Sorbonne University, Department of Internal Medicine, AP-HP, Hôpital Tenon, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA), Paris, France; Department of Pediatrics, National Reference Center for Auto-inflammatory Diseases and Amyloidosis, CEREMAIA, Versailles Hospital, Versailles, France
| | - Véronique Hentgen
- Department of Pediatrics, National Reference Center for Auto-inflammatory Diseases and Amyloidosis, CEREMAIA, Versailles Hospital, Versailles, France
| | - Gilles Grateau
- Sorbonne University, Department of Internal Medicine, AP-HP, Hôpital Tenon, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA), Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne University, Department of Internal Medicine, AP-HP, Hôpital Tenon, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA), Paris, France.
| |
Collapse
|
21
|
Bourguiba R, Kyheng M, Koné-Paut I, Rouzaud D, Avouac J, Devaux M, Abdallah NA, Fautrel B, Ferreira-Maldent N, Langlois V, Ledoult E, Nielly H, Queyrel V, Sellam J, Tieulie N, Chazerain P, Evon P, Labreuche J, Savey L, Hentgen V, Grateau G, Georgin-Lavialle S. COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI - the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases. RMD Open 2022; 8:rmdopen-2021-002063. [PMID: 35537796 PMCID: PMC9091487 DOI: 10.1136/rmdopen-2021-002063] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Accepted: 02/04/2022] [Indexed: 11/04/2022] Open
Abstract
Objective There is little known about SARS-CoV-2 infection in patients with systemic autoinflammatory disease (SAID). This study aimed to describe epidemiological features associated with severe disease form and death. Mortality between patients with and without SAID hospitalised for SARS-CoV-2 infection was compared. Methods A national multicentric prospective cohort study was conducted from the French Rheumatic and Musculoskeletal Diseases (RMD) COVID-19 cohort. Patients with SAID were matched with patients with non-SAID on age±7 years, gender and number of comorbidities to consider important confounding factors. Impact of SAID on severity of SARS-CoV-2 infection was analysed using multinomial logistic regression for severity in three classes (mild, moderate and severe with mild status as reference). Fine-Gray regression model for length of hospital stay and binomial logistic regression model for risk of death at 30 days. Results We identified 117 patients with SAID (sex ratio 0.84, 17 children) and compared them with 1545 patients with non-autoinflammatory immune-mediated inflammatory disorders (non-SAID). 67 patients had a monogenic SAID (64 with familial Mediterranean fever). Other SAIDs were Behçet’ disease (n=21), undifferentiated SAID (n=16), adult-onset Still disease (n=9) and systemic-onset juvenile idiopathic arthritis (n=5). Ten adults developed severe form (8.6%). Six patients died. All children had a benign disease. After matching on age±7 years, sex and number of comorbidities, no significant difference between the two groups in length of stay and the severity of infection was noted. Conclusion As identified in the whole French RMD COVID-19 cohort, patients with SAID on corticosteroids and with multiple comorbidities are prone to develop more severe COVID-19 forms.
Collapse
Affiliation(s)
- Rim Bourguiba
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; national Reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | - Maeva Kyheng
- Univ. Lille, CHU Lille, ULR 2694 - METRICS : évaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France, CHU Lille, Département de Biostatistiques, F-59000 Lille, France, Université de Lille, Lille, France
| | - Isabelle Koné-Paut
- Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires de l'enfant, Hôpital Bicêtre, AP HP, Université Paris Sud, Bicètre, France
| | - Diane Rouzaud
- Department of internal medicine, Bichat hospital, Paris, France, Bichat Hospital, Paris, France
| | - Jerome Avouac
- Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, Hôpital Cochin, Paris, France
| | - Mathilde Devaux
- CHI Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, France
| | - Nassim Ait Abdallah
- Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Centre de Reference des Maladies autoimmunes systemiques Rares d'Ile-de-France MATHEC, AP-HP, Hopital Saint-Louis, Paris, France, Université de Paris, IRSL, Recherche clinique appliquée à l'hématologie, EA, Paris, France, Hôpital Saint-Louis, Paris, France
| | - Bruno Fautrel
- Sorbonne Université - Assistance Publique Hôpitaux de Paris, Pitié Salpêtrière University Hospital, Dept of Rhumatology, Reference Center for Rare Diseases CEREMAIA (ERN RITA), Paris, France. ii) Pierre Louis Institute of Epidemiology and Public Health, INSERM UMRS 1136, PEPITES team, Assistance Publique-Hopitaux de Paris, Paris, France
| | | | | | - Emmanuel Ledoult
- Service de Médecine Interne, Centre de Référence des Maladies Auto-immunes et Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, F-59000 Lille, France 2- Inserm, U1286, F-59000 Lille, France, CHRU de Lille, Lille, France
| | - Hubert Nielly
- Hôpital d'Instructions des Armées Bégin, Saint Mande, France
| | | | - Jérémie Sellam
- Rheumatology, INSERM UMRS_938, Sorbonnes Université UPMC Univ Paris 06, St-Antoine Hospital, DHU i2B, Paris, France
| | - Nathalie Tieulie
- Service de Rhumatologie, Hôpital Pasteur, Centre Hospitalier Universitaire, Université de Nice Sophia Antipolis, Nice, France
| | - Pascal Chazerain
- Internal Medicine and Rheumatology, Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France
| | - Philippe Evon
- Internal Medecine department, CH de Bar-Le-Duc, Bar-le-Duc, France
| | | | - Léa Savey
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; national Reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | - Veronique Hentgen
- CeReMAI-Departement of Pediatrics Department of general pediatrics, Andre Mignot hospital, Versailles, CEREMAIA, France, Hôpital Mignot, Le Chesnay, France
| | - Gilles Grateau
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; national Reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; national Reference center for autoinflammatory diseases and AA amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | | |
Collapse
|
22
|
Rech JS, Quirin N, Buob D, Georgin-Lavialle S, Grateau G, Cazorla C. AA amyloidosis of unknown origin in New-Caledonia with focus on the association with gout: a consecutive case series of 20 patients. Amyloid 2022; 29:68-69. [PMID: 34817314 DOI: 10.1080/13506129.2021.2007475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Jean-Simon Rech
- Department of Internal Medicine and Nephrology, CHT Gaston Bourret Noumea, New Caledonia
| | - Nicolas Quirin
- Department of Internal Medicine and Nephrology, CHT Gaston Bourret Noumea, New Caledonia
| | - David Buob
- Department of Pathology, APHP, Tenon Hospital Paris, France
| | | | - Gilles Grateau
- Department of Internal Medicine, CeRéMAIA, APHP, Tenon Hospital Paris, France
| | - Cecile Cazorla
- Department of Infectious Disease, CHT Gaston Bourret Noumea, New Caledonia
| |
Collapse
|
23
|
Alhenc-Gelas M, Lefevre G, Bachmeyer C, M'Bappe P, Ouahabi S, Grateau G, Letavernier E, Steichen O. Poor performance of albumin or protein-adjusted plasma calcium to diagnose dyscalcemia in hospitalized patients: A confirmatory study in a general internal medicine department. Rev Med Interne 2021; 43:206-211. [PMID: 34953621 DOI: 10.1016/j.revmed.2021.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 11/13/2021] [Accepted: 11/28/2021] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Hypo- and hypercalcemia are common and some causes require urgent diagnosis and treatment. Measurement of ionized calcium is the reference test to diagnose calcium disorders but total calcium adjusted for protein or albumin concentration is more often used. METHODS Patients hospitalised in a general internal medicine department from September 2013 to December 2015 who had a total plasma calcium concentration and a serum albumin or protein concentration measured within 24h of a ionized calcium blood measurement were included. Total calcium was adjusted for protein or albumin concentration using widely used formulas and compared to ionized calcium as the gold standard. RESULTS Among 210 included patients, 46 (22%) had hypocalcemia, 124 (59%) normocalcemia and 40 (19%) hypercalcemia according to ionized calcium concentration. Total calcium had 50% sensitivity and 95% specificity to diagnose hypocalcemia and a 93% sensitivity and 89% specificity to diagnose hypercalcemia. Adjusting total calcium for protein or albumin concentrations did not increase and sometimes decreased diagnostic accuracy. CONCLUSION Total calcium, with or without albumin/protein adjustment, is poorly sensitive to screen for hypocalcemia. Unadjusted total calcium is as sensitive as protein- or albumin-adjusted total calcium to screen for hypercalcemia. These data argue against the use of albumin- or protein-adjusted calcium. Ionized calcium measurement should be performed to confirm dyscalcemia in patients with abnormal total calcium concentration and to rule out hypocalcemia in patients with total calcium concentration in the lower range of normal values.
Collapse
Affiliation(s)
- M Alhenc-Gelas
- Service de médecine interne, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France
| | - G Lefevre
- Laboratoire de biochimie, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France
| | - C Bachmeyer
- Service de médecine interne, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France
| | - P M'Bappe
- Service de médecine interne, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France
| | - S Ouahabi
- Laboratoire de biochimie, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France
| | - G Grateau
- Service de médecine interne, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France
| | - E Letavernier
- Explorations fonctionnelles rénales, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France
| | - O Steichen
- Service de médecine interne, Assistance Publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, 75020 Paris, France; Sorbonne université, Inserm, Institut Pierre-Louise d'épidémiologie et de santé publique (IPLESP, UMR-S1136), 75006 Paris, France.
| |
Collapse
|
24
|
Kluger N, Bourguiba R, Delplanque M, Hentgen V, Kone-Paut I, Savey L, Grateau G, Georgin-Lavialle S. Tattooing and autoinflammatory diseases: a study among 197 French patients from the JIR cohort. J Eur Acad Dermatol Venereol 2021; 36:e363-e365. [PMID: 34923687 DOI: 10.1111/jdv.17886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Revised: 11/29/2021] [Accepted: 12/15/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Nicolas Kluger
- Assistance publique-Hôpitaux de Paris, Bichat-Claude Bernard Hospital, "Tattoo" consultation, Department of dermatology, 75018, Paris, France.,University of Helsinki and Helsinki University Hospital, Department of Dermatology, Allergology and Venereology, Helsinki, Finland
| | - Rim Bourguiba
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoire (CEREMAIA), France
| | - Marion Delplanque
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoire (CEREMAIA), France
| | - Véronique Hentgen
- Department of general pediatrics, Andre Mignot hospital, Versailles, CEREMAIA, France
| | - Isabelle Kone-Paut
- University of Paris Saclay, Department of pediatric rheumatology and CEREMAIA, Bicêtre hospital, APHP, France
| | - Léa Savey
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoire (CEREMAIA), France
| | - Gilles Grateau
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoire (CEREMAIA), France
| | - Sophie Georgin-Lavialle
- Sorbonne University, AP-HP, Tenon Hospital, Internal Medicine Department, 4 rue de la Chine, 75020, Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoire (CEREMAIA), France
| |
Collapse
|
25
|
Deshayes S, Bourguiba R, Haymann JP, Savey L, Aouba A, Buob D, Boffa JJ, Grateau G, Georgin-Lavialle S. Abnormal electrochemical skin conductance values in patients with AA amyloidosis. Amyloid 2021; 28:273-274. [PMID: 34180328 DOI: 10.1080/13506129.2021.1942827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Samuel Deshayes
- Department of Internal Medicine, Normandie Univ, UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Caen, France.,French National Reference center for AA amyloidosis (CEREMAIA), Paris, France
| | - Rim Bourguiba
- French National Reference center for AA amyloidosis (CEREMAIA), Paris, France.,Sorbonne University, GRAASU GRC, Department of Internal Medicine, CEREMAIA, Tenon hospital, AP-HP, Paris, France
| | - Jean-Philippe Haymann
- Sorbonne University, Department of Physiology, INSERM UMR_S 1155, Tenon hospital, AP-HP, Paris, France
| | - Léa Savey
- French National Reference center for AA amyloidosis (CEREMAIA), Paris, France.,Sorbonne University, GRAASU GRC, Department of Internal Medicine, CEREMAIA, Tenon hospital, AP-HP, Paris, France.,Sorbonne University Clinical Research Group N°28 on AA amyloidosis (GRAASU), Paris, France
| | - Achille Aouba
- Department of Internal Medicine, Normandie Univ, UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Caen, France
| | - David Buob
- Sorbonne University, Department of Pathology, Tenon hospital, AP-HP, Paris, France
| | - Jean-Jacques Boffa
- Sorbonne University, Department of Nephrology, INSERM UMR_S 1155, Tenon hospital, AP-HP, Paris, France
| | - Gilles Grateau
- French National Reference center for AA amyloidosis (CEREMAIA), Paris, France.,Sorbonne University, GRAASU GRC, Department of Internal Medicine, CEREMAIA, Tenon hospital, AP-HP, Paris, France.,Sorbonne University Clinical Research Group N°28 on AA amyloidosis (GRAASU), Paris, France
| | - Sophie Georgin-Lavialle
- French National Reference center for AA amyloidosis (CEREMAIA), Paris, France.,Sorbonne University, GRAASU GRC, Department of Internal Medicine, CEREMAIA, Tenon hospital, AP-HP, Paris, France.,Sorbonne University Clinical Research Group N°28 on AA amyloidosis (GRAASU), Paris, France
| | | |
Collapse
|
26
|
Terré A, Colombat M, Cez A, Martin C, Diet C, Brechignac S, Oghina S, Bodez D, Faguer S, Savey L, Galland J, Boffa JJ, Grateau G, Jaccard A, Buob D, Georgin-Lavialle S. AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance"? Int J Clin Pract 2021; 75:e14817. [PMID: 34490695 DOI: 10.1111/ijcp.14817] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Revised: 07/23/2021] [Accepted: 09/03/2021] [Indexed: 12/23/2022] Open
Abstract
INTRODUCTION AL amyloidosis is caused by the proliferation of an immunoglobulin-secreting B cell clone. AA amyloidosis is a rare complication of chronic inflammation. However, some patients present with diseases combining monoclonal immunoglobulin production and chronic inflammation. The aim of this work was to describe cases of AA amyloidosis associated with monoclonal gammopathies. PATIENTS AND METHODS We reviewed all patients reported in French national amyloid centres presenting with AA amyloidosis and monoclonal gammopathy and performed a literature review. The quality of AA amyloidosis diagnosis and the causal relationship with monoclonal gammopathy were assessed. RESULTS In total, four patients from our centres and eight from the literature fulfilled the inclusion criteria. The haematological disorders presenting with monoclonal gammopathy were as follows: Waldenström macroglobulinaemia (n = 8), Schnitzler syndrome (n = 2), multiple myeloma (n = 1) and monoclonal gammopathy of undetermined significance (n = 1). Treatment strategies varied among the cases, with the treatment of the haematological disorder in 4 and anti-inflammatory treatment in 2. CONCLUSION Monoclonal gammopathies might be a rare and poorly known cause of AA amyloidosis. Such monoclonal gammopathies could be named "monoclonal gammopathies of inflammatory significance."
Collapse
Affiliation(s)
- Alexandre Terré
- Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, Paris, France
- Laboratoire d'Excellence GR-Ex, Institut Imagine, INSERM U1163, CNRS ERL 8254, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France
| | | | - Alexandre Cez
- Department of Nephrology, Sorbonne University, Tenon Hospital, Paris, France
| | - Claire Martin
- Rheumatology Department, La Rochelle Hospital, La Rochelle, France
| | - Carine Diet
- Nephrology Department, Henri Mondor Hospital, Creteil, France
| | | | - Silvia Oghina
- Cardiology Department, Henri Mondor Hospital, National Reference Centre of Cardiac Amyloidosis, Creteil, France
| | - Diane Bodez
- Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France
| | - Stanislas Faguer
- Département de Néphrologie et Transplantation d'Organes, CHU de Toulouse, Toulouse, France
| | - Léa Savey
- Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, Paris, France
| | - Joris Galland
- Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, Paris, France
| | | | - Gilles Grateau
- Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, Paris, France
- Inserm UMRS_933, et laboratoire de génétique, Faculté de médecine, Sorbonne University, Trousseau Hospital, AP-HP, Paris, France
| | - Arnaud Jaccard
- Haematology Department, CHU Dupuytren, National Reference Center for AL Amyloidosis Limoges, France
| | - David Buob
- Department of Pathology, Sorbonne University, Tenon Hospital, Paris, France
| | - Sophie Georgin-Lavialle
- Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne University, AP-HP, Tenon Hospital, Paris, France
- Inserm UMRS_933, et laboratoire de génétique, Faculté de médecine, Sorbonne University, Trousseau Hospital, AP-HP, Paris, France
| |
Collapse
|
27
|
Fayand A, Chasset F, Boutboul D, Queyrel V, Tieulié N, Guichard I, Dupin N, Franck N, Cohen P, Bessis D, Guenno GL, Koné-Paut I, Belot A, Bonhomme A, Ducharme-Bénard S, Grateau G, Sarrabay G, Touitou I, Boursier G, Georgin-Lavialle S. DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases. Semin Arthritis Rheum 2021; 51:1170-1179. [PMID: 34571400 DOI: 10.1016/j.semarthrit.2021.09.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 08/31/2021] [Accepted: 09/13/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Deficiency of adenosine deaminase 2 (DADA2) is a rare autoinflammatory disease usually presenting before the age of 10 years. Non-specific clinical features or late-onset presentation may delay its diagnosis until adulthood. OBJECTIVE To determine whether DADA2 diagnosed in adulthood is associated with specific characteristics compared to DADA2 diagnosed in childhood. METHODS We pooled a cohort of 12 adult DADA2 patients followed in France with cases identified through a systematic literature review. For each patient, we determined the type of clinical presentation and assessed six key organ involvements. RESULTS A total of 306 cases were included. Among the 283 patients with available data regarding age at diagnosis, 140 were diagnosed during adulthood and 143 during childhood. The vascular presentation of DADA2 was more frequent in the adult diagnosis group (77.9% vs. 62.9%, p < 0.01), whereas the hematological presentation (bone marrow failure) prevailed in the pediatric diagnosis group (10.0% vs. 20.3% p = 0.02). In patients with vasculopathy, severe skin manifestations developed in 35% and 10% of the adult and pediatric diagnosis groups, respectively. Conversely, fewer strokes occurred in the adult group presenting with systemic vasculopathy (54% vs. 81%). Symptomatic humoral immune deficiency (HID) was rarely a clinical presentation in itself (5% and 2.8%) but accompanied other phenotypes of DADA2, especially the hematological phenotype in the adult group (33% vs. 4%). CONCLUSION DADA2 diagnosed in adulthood presents more often with a vascular phenotype and less often with bone marrow failure than DADA2 diagnosed in childhood. Adults diagnosed with DADA2 vasculopathy display more severe skin involvement but fewer strokes.
Collapse
Affiliation(s)
- Antoine Fayand
- Sorbonne Université, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris, France
| | - François Chasset
- Sorbonne Université, AP-HP, Tenon Hospital, Department of Dermatology, Paris, France
| | - David Boutboul
- AP-HP, Saint-Louis Hospital, Department of Clinical Immunology, Paris University, Paris, France
| | - Viviane Queyrel
- Pasteur 2 Hospital, Department of Rheumatology, Cote d'Azur University, Nice University Hospital, Nice, France
| | - Nathalie Tieulié
- Pasteur 2 Hospital, Department of Rheumatology, Cote d'Azur University, Nice University Hospital, Nice, France
| | - Isabelle Guichard
- Hôpital Nord, Department of Internal Medicine, Jean Monnet University, Saint-Etienne University Hospital, Saint-Etienne, France
| | - Nicolas Dupin
- AP-HP, Cochin Hospital, Department of Dermatology, Paris Universisty, Paris, France
| | - Nathalie Franck
- AP-HP, Cochin Hospital, Department of Dermatology, Paris Universisty, Paris, France
| | - Pascal Cohen
- Service de Médecine Interne, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Université de Paris, Paris F-75006, France
| | - Didier Bessis
- Saint-Eloi Hospital, Department of Dermatology, Montpellier University, Montpellier University Hospital, Montpellier, France
| | - Guillaume Le Guenno
- Estaing Hospital, Department of Internal Medicine, Clermont-Auvergne University, Clermont Ferrand University Hospital, Clermont Ferrand, France
| | - Isabelle Koné-Paut
- AP-HP, Bicêtre Hospital, Department of Pediatric Rheumatology, Paris-Saclay University, Le-Kremlin-Bicêtre, France
| | - Alexandre Belot
- Hospices Civils de Lyon, Femme Mère Enfant Hospital, Centre de référence des rhumatismes inflammatoires et maladies autoimmunes de l'enfant (RAISE), Lyon University, Lyon, France
| | - Axelle Bonhomme
- Metz-Thionville Regional Hospital, Department of Dermatology, Metz, France
| | | | - Gilles Grateau
- Sorbonne Université, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris, France
| | - Guillaume Sarrabay
- Arnaud de Villeneuve Hospital, Laboratory of rare and autoinflammatory genetic diseases, Centre de référence des maladies auto-Inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Montpellier University, Montpellier University Hospital, Montpellier, France
| | - Isabelle Touitou
- Arnaud de Villeneuve Hospital, Laboratory of rare and autoinflammatory genetic diseases, Centre de référence des maladies auto-Inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Montpellier University, Montpellier University Hospital, Montpellier, France
| | - Guilaine Boursier
- Arnaud de Villeneuve Hospital, Laboratory of rare and autoinflammatory genetic diseases, Centre de référence des maladies auto-Inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Montpellier University, Montpellier University Hospital, Montpellier, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris, France.
| |
Collapse
|
28
|
Breillat P, Pourcher V, Deshayes S, Buob D, Cez A, Michel PA, Boffa JJ, Langlois V, Grateau G, Georgin-Lavialle S. AA Amyloidosis in the Course of HIV Infection: A Report of 19 Cases Including 4 New French Cases and a Comprehensive Review of Literature. Nephron Clin Pract 2021; 145:675-683. [PMID: 34265778 DOI: 10.1159/000516982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Accepted: 05/02/2021] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION HIV infection has been recently retained as an unclear cause of AA amyloidosis. Our aim was to investigate cases of AA amyloidosis associated with HIV infection to understand if it could be considered as a cause of AA amyloidosis. METHODS A comprehensive literature review was conducted as well as retrospective study from French cases collected from our national reference center for AA amyloidosis. RESULTS Altogether, 19 patients with AA amyloidosis and HIV infection were found with 68% of men and median age at amyloidosis diagnosis of 38 years (range 28-75 years). Clinical presentation was nephrotic syndrome in 94% (n = 17/18). Among patients with renal involvement and assessable outcome (n = 17), 11 (64.7%) progressed to chronic kidney disease, with 6 (35%) end-stage renal disease. Seventy-five percent of patients had uncontrolled HIV infection and 71.4% CD4 counts <400/mm3 at amyloidosis diagnosis. Repeated or chronic bacterial or fungal infection was found in 47% of cases and a history of parenteral drug use in 55% of patients. Three patients had no classical or at least no suspected AA amyloidosis cause found or reported. CONCLUSIONS AA Amyloidosis is a rare condition in HIV patients with common renal involvement and significant risk of progression to chronic renal insufficiency. Because of the frequency related to other inflammatory conditions in this population, HIV is probably not an independent risk factor for AA amyloidosis.
Collapse
Affiliation(s)
- Paul Breillat
- Department of Internal Medicine, Sorbonne University, AP-HP, Tenon Hospital, Centre De Référence Des Maladies Auto-Inflammatoires Et Des Amyloses D'origine Inflammatoire (CEREMAIA), Paris, France
| | - Valérie Pourcher
- Department of Infectious Diseases, Sorbonne University, APHP, Pitié Salpétrière Hospital, INSERM 1136, Paris, France
| | - Samuel Deshayes
- Department of Internal Medicine, Normandie University, UNICAEN, CHU De Caen Normandie, Caen, France
| | - David Buob
- Department of Biopathology, Sorbonne University, AP-HP, Tenon Hospital, Paris, France
| | - Alexandre Cez
- Department of Nephrology, Sorbonne University, AP-HP, Tenon Hospital, Paris, France
| | | | - Jean-Jacques Boffa
- Department of Nephrology, Sorbonne University, AP-HP, Tenon Hospital, Paris, France
| | - Vincent Langlois
- Department of Internal Medicine, Jacques Monod Hospital, Le Havre, France
| | - Gilles Grateau
- Department of Internal Medicine, Sorbonne University, AP-HP, Tenon Hospital, Centre De Référence Des Maladies Auto-Inflammatoires Et Des Amyloses D'origine Inflammatoire (CEREMAIA), Paris, France
| | - Sophie Georgin-Lavialle
- Department of Internal Medicine, Sorbonne University, AP-HP, Tenon Hospital, Centre De Référence Des Maladies Auto-Inflammatoires Et Des Amyloses D'origine Inflammatoire (CEREMAIA), Paris, France
| |
Collapse
|
29
|
Delplanque M, Ducharme-Bénard S, Moguelet P, Chasset F, Grateau G, Georgin-Lavialle S, Bachmeyer C. Is neutrophilic dermatosis a manifestation of familial Mediterranean fever? Scand J Rheumatol 2021; 51:42-49. [PMID: 34159892 DOI: 10.1080/03009742.2021.1904588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Objectives: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disease. It is associated with MEFV mutations. Its main features are recurrent episodes of fever and serositis. Patients can display dermatological manifestations such as erysipelas-like erythema, generally considered as a neutrophilic dermatosis (ND). It has been suggested that FMF can be associated with other types of ND. Our aim was to perform a systematic review of the literature to assess the link between ND and FMF.Method: A systematic review of the literature was performed using MEDLINE from 1946 to 2018. Three independent investigators identified reports of non-erysipelas-like erythema neutrophilic dermatosis (NEND) associated with FMF, selected the criteria to establish the diagnosis of FMF and ND, and evaluated the link between the two conditions. FMF-associated NEND was supported by confirmation of both diagnoses and exclusion of other causes of ND.Results: Eighteen articles were selected. Nine articles reported FMF patients with the following NEND: neutrophilic panniculitis (n = 4), Sweet syndrome (n = 6), and pyoderma gangrenosum (n = 1). None of these cases was supported by histological confirmation, fulfilled diagnostic criteria for definitive or probable FMF, or confirmed the exclusion of all the most frequent diseases associated with NEND. As a result, there is insufficient evidence to support a potential relationship between NEND and FMF.Conclusions: The association between FMF and NEND remains unclear. In FMF patients with NEND, every differential diagnosis and alternative cause of NEND should be excluded before drawing any conclusions about a potential causal relationship.
Collapse
Affiliation(s)
- M Delplanque
- Internal Medicine Department, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | - S Ducharme-Bénard
- Internal Medicine Department, Sacré-Coeur Hospital, Montreal, Canada
| | - P Moguelet
- Anatomopathology Department, Tenon Hospital, Paris, France
| | - F Chasset
- Dermatology Department, Tenon Hospital, Paris, France
| | - G Grateau
- Internal Medicine Department, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | - S Georgin-Lavialle
- Internal Medicine Department, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | - C Bachmeyer
- Internal Medicine Department, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| |
Collapse
|
30
|
Bourguiba R, Delplanque M, Caroline V, Savey L, Grateau G, Hentgen V, Georgin-Lavialle S. La fièvre méditerranéenne familiale est-elle uns situation à risque de développer une forme grave d’infection par la COVID19 ? Résultat d’une étude rétrospective sur 627 patients en période et zone endémique en France. Rev Med Interne 2021. [PMCID: PMC8192023 DOI: 10.1016/j.revmed.2021.03.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Introduction La nouvelle pandémie mondiale (COVID19) causée par le coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2) est responsable de nombreux décès dans le monde entier au cours des derniers mois. Au cours des formes graves, il a été noté une réponse inflammatoire exagérée connue sous le nom de “orage cytokinique”. Ceci a soulevé la question de la sensibilité et de la gravité de l’infection par le SRAS-CoV2 chez les patients présentant une hyperactivation génétique de l’immunité innée tels que la fièvre méditerranéenne familiale (FMF). En outre, les patients avec FMF prennent de la colchicine au long cours, médicament qui a été testé chez des patients infectés par le SRAS-CoV2 avec des résultats contradictoires [1]. Patients et méthodes Étude menée sur l’infection par le SRAS-CoV2 chez les patients atteints de FMF suivis dans 2 sites du centre de référence national des maladies autoinflammatoires en région parisienne et inclus dans la JIR cohorte, une base de données européenne multicentrique. Les patients adultes et pédiatriques inclus répondaient aux critères internationaux de FMF et avaient un diagnostic génétique confirmé. Résultats Les patients identifiés (n = 627) ont été invités à répondre à un bref questionnaire soit en consultation, soit par téléphone, soit par courrier électronique sur une possible infection par le SARS-CoV2 pendant la période de mars à juin 2020 ; 342 patients ont répondu à l’enquête. Le diagnostic était retenu si le patient présentait des symptômes cliniques avec PCR ou sérologie positive ou scanner thoracique typique. Au total, 27 patients FMF (7,8 % des répondants ; sexe ratio 1/1) ont contracté le virus. Tous les 27 patients FMF-COVID+ sauf un prenaient de la colchicine quotidiennement depuis une période médiane de 23 ans, la dose moyenne de colchicine était de 1 mg/jour. Quatre recevaient en plus un inhibiteur de l’IL-1. Parmi les 27 patients FMF-COVID+, sept symptomatiques ont été hospitalisés (25 %) et six ont eu besoin d’oxygène ; trois (11 %) ont développé un syndrome de détresse respiratoire aiguë nécessitant des soins intensifs pour une ventilation mécanique et une hémodialyse. Deux patients sont décédés (7 %) mais présentaient respectivement 3 et 4 comorbidités pour une infection grave par le SRAS-CoV2 ; le troisième patient, âgé de 40 ans, souffrait d’hypertension et d’obésité. Les patients âgés de plus de 65 ans représentaient 17 % de l’ensemble de la cohorte FMF-COVID + ; 75 % ont été hospitalisés et ont eu besoin d’oxygène ; l’un d’eux est décédé. Trois patients FMF-COVID + avaient une amylose AA : 2 ont été hospitalisés et un est décédé. Aucun traitement anti-viral supplémentaire n’a été administré. Les 5 survivants après hospitalisation sont rentrés chez eux. Aucun d’entre eux n’a présenté de signes cliniques de crise de FMF lors de l’infection par le SRAS-CoV2. Discussion Le profil des patients FMF atteints d’une forme grave ou potentiellement mortelle par le SRAS-CoV2 était le même que celui de la population générale. Ainsi, seuls les patients FMF présentant des facteurs de risque connus (tels que âge avancé, maladie rénale chronique, hypertension, maladie vasculaire, obésité et dysfonctionnement pulmonaire) ont développé une infection grave par le SARS-CoV2 [2]. Cette étude n’est pas en faveur d’un surrisque en soi de développer une infection sévère à SRAS-CoV2 en présence d’une maladie autoinflammatoire monogénique touchant un inflammasome. Aucune conclusion formelle ne peut être tirée sur l’effet préventif de la colchicinothérapie au long cours, bien que ce travail rétrospectif porte sur une large cohorte de patients traités par colchicine depuis plusieurs années. Il est difficile de conclure à l’efficacité du traitement par inhibiteur d’IL1 vis-à-vis l’infection par le SRAS-CoV-2 chez les patients FMF, mais 50 % des patients traités au long cours sont décédés mais avaient plusieurs comorbidités ; et des publications récentes semblent plaider en faveur de l’efficacité de l’anakinra dans l’infection grave par le SRAS-CoV-2 [3]. Conclusion La FMF ne semble pas constituer un facteur de risque de développer une forme sévère d’infection par SARS-CoV2 chez les patients traités au long cours par de la colchicine quotidienne, par rapport à la population générale.
Collapse
|
31
|
Bourguiba R, Savey L, Dumont A, Ardois S, Vergneault H, Giurgea I, Amselem S, Grateau G, Georgin-Lavialle S. Errance diagnostique dans la fièvre méditerranéenne familiale : à propos de 85 cas dans une cohorte de 560 patients adultes. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Abstract
BACKGROUND Amyloidoses are a heterogeneous group of systemic diseases characterised by extracellular accumulation of insoluble amyloid fibrils derived from unfolded proteins. Inflammatory (AA) amyloidosis can complicate various inflammatory disorders that are associated with a sustained acute phase response and serum amyloid A (SAA) protein overproduction. Chronic infections were the first recognised cause of amyloidoses. However, with the better management of underlying diseases, the frequency of AA amyloidosis is decreasing. PURPOSE The aim of this overview was to discuss the several infections associated with AA amyloidosis and the relative frequency of infections as aetiological factors. METHODS A search of the literature was performed using the PubMed database using the MeSH terms "Amyloidosis" and "Infections," from inception to December 31st, 2019. Articles written in other languages than English or French were excluded. RESULTS The frequency of AA amyloidosis secondary to infections decreased from more than 50% to less than 20% after the 2000s, with a parallel increase in the frequency of AA amyloidosis secondary to inflammatory diseases and to an unknown cause. CONCLUSION Whereas new antibiotics have been developed and sanitary conditions are better, infections still represent 5%-30% of the causes of AA amyloidosis, including in developed countries. These data argue for better screening of chronic infections to prevent AA amyloidosis and the development of new strategies to manage recurrent infections.
Collapse
Affiliation(s)
- Samuel Deshayes
- Service de médecine interne, Normandie University, UNICAEN, CHU de Caen Normandie, Caen, France
| | - Achille Aouba
- Service de médecine interne, Normandie University, UNICAEN, CHU de Caen Normandie, Caen, France
| | - Gilles Grateau
- Sorbonne Université, Service de médecine interne, GRC-28 (GRAASU), Centre national de référence des maladies autoinflammatoires et des amyloses inflammatoires (CEREMAIA), hôpital Tenon, AP-HP, Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, Service de médecine interne, GRC-28 (GRAASU), Centre national de référence des maladies autoinflammatoires et des amyloses inflammatoires (CEREMAIA), hôpital Tenon, AP-HP, Paris, France
| |
Collapse
|
33
|
Deshayes S, Bourguiba R, Haymann JP, Lea.Savey@aphp.Fr>; LSF, Aouba A, Grateau G, Georgin-Lavialle S. POS1343 ABNORMAL ELECTROCHEMICAL SKIN CONDUCTANCE VALUES IN PATIENTS WITH AA AMYLOIDOSIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Clinical manifestations are scarce in AA amyloidosis (AAA) and, contrary to other types of amyloidosis, involvement of the peripheral nervous system was rarely reported in AAA. However, the usual absence of hypertension despite chronic renal failure and the digestive involvement may be secondary to dysautonomia, but the autonomic nervous system has rarely been studied in AAA (1). Measure of the electrochemical skin conductance (ESC) is a simple and reproducible method to evaluate the function of eccrine sweat glands, which are innervated by small non-myelinated C fibers, and patients with AL and hereditary transthyretin amyloidoses show decreased ESC values (2,3).Objectives:To evaluate ESC values by Sudoscan in patients with AAA.Methods:Patients diagnosed as having AAA based on positive immunohistochemistry with an anti-serum amyloid A antibody followed at the national reference center for AAA in Tenon Hospital between July, 2017 and September, 2020, were routinely assessed for ESC with FDA approved Sudoscan (Impeto Medical, Paris, France). An ESC value above 60 microSiemens (µS) or 70 µS were considered normal for hands or feet, respectively. Categorical variables are reported as percentages and continuous variables are expressed as means±standard deviation. Correlations between age, body mass index (BMI), hemoglobin levels, C-reactive protein levels, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation (defined as 0 for dialysis patients) and ESC values were calculated using the nonparametric Spearman test. GraphPad Prism Version 7 software (GraphPad Software, San Diego, California, USA) was used for statistical analyses. A p-value <0.05 was considered as statistically significant.Results:Overall, 32 patients (16 women) were included, with a mean age of 57.4±13.6 years and a mean BMI of 25.2±6.8 kg/m2. Six (19%) had diabetes mellitus, and 5 (16%) had a kidney transplantation. The main causes of AAA were: monogenic autoinflammatory diseases (n=11, 34%, including 9 patients with familial Mediterranean fever), chronic and/or recurrent infections (n=5, 16%), obesity (n=3, 9%) and undefined (n=3, 9%). The mean hands’ ESC values was normal at 65.5±21.1 µS, although 8 (25%) patients had ESC values below 60 µS, including 2 diabetic patients. In contrast, the mean feet’s ESC values was abnormal at 62.7±23.7 µS, including half of the patients with ESC values below 70 µS (2 diabetic patients). Eight patients had abnormal ESC values only for feet, and 1 had abnormal values only for hands. Apart from a significant correlation between feet and hands’ ESC values (p<0.0001), only the estimated glomerular filtration rate was significantly associated with hands’ ESC values (p<0.01).Conclusion:To our knowledge, this is the first study to assess ESC in AAA. Feet’s ESC values were moderately impaired in half of the patients with AAA. Therefore, this study reinforces the previously reported alterations in the autonomic nervous system in patients with AAA that should probably be searched for in these patients. In addition, the identification of an alteration of the ESC values cannot allow to distinguish the type of amyloidosis.References:[1]Nussinovitch U, Volovitz B, Nussinovitch M, Lidar M, Feld O, Nussinovitch N, et al. Abnormal heart rate variability in AA amyloidosis of familial Mediterranean fever. Amyloid 2011;18:206–10.[2]Montcuquet A, Duchesne M, Roussellet O, Jaccard A, Magy L. Electrochemical skin conductance values suggest frequent subclinical autonomic involvement in patients with AL amyloidosis. Amyloid 2020;27:215–6.[3]Fortanier E, Delmont E, Verschueren A, Attarian S. Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 2020;131:1129–33.Disclosure of Interests:None declared
Collapse
|
34
|
Savey L, Grateau G, Georgin-Lavialle S. [Familial Mediterranean fever in 2020]. Nephrol Ther 2021; 17S:S119-S125. [PMID: 33910693 DOI: 10.1016/j.nephro.2020.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Accepted: 02/05/2020] [Indexed: 10/21/2022]
Abstract
Familial Mediterranean fever is the most frequent autoinflammatory disease with autosomal recessive transmission. Most patients carry mutations in the MEFV gene encoding the protein marenostrin/pyrin. It is characterised by short ant recurrent attacks of fever and serositis with abdominal or thoracic pain, usually lasting less than 3 days, raised inflammatory biologic markers in an individual of Mediterranean origin. Colchicine has been shown to be effective in prevention of inflammatory attacks and development of amyloidosis which is responsible of nephrotic syndrome and chronic renal failure. Better knowledge in pathogenic mechanisms permitted identification of interleukin-1 beta (Il-1 β) as the main cytokine target. Anti-IL-1 therapy must be considered as a second line treatment in case of persistent inflammation or colchicine intolerance.
Collapse
Affiliation(s)
- Lea Savey
- Service de médecine interne, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (Cerémaia), 4, rue de la Chine, 75020 Paris, France; Sorbonne université, 4, rue de la Chine, 75020 Paris, France
| | - Gilles Grateau
- Service de médecine interne, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (Cerémaia), 4, rue de la Chine, 75020 Paris, France; Sorbonne université, 4, rue de la Chine, 75020 Paris, France.
| | - Sophie Georgin-Lavialle
- Service de médecine interne, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (Cerémaia), 4, rue de la Chine, 75020 Paris, France; Sorbonne université, 4, rue de la Chine, 75020 Paris, France
| |
Collapse
|
35
|
Lacout C, Savey L, Bourguiba R, Giurgea I, Amselem S, Hoyeau N, Galland J, Amiot X, Grateau G, Ducharme-Bénard S, Georgin-Lavialle S. "Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france". Helicobacter 2021; 26:e12789. [PMID: 33586832 DOI: 10.1111/hel.12789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 01/18/2021] [Accepted: 01/19/2021] [Indexed: 12/09/2022]
Abstract
INTRODUCTION Familial Mediterranean Fever (FMF), the most common monogenic auto-inflammatory disease, is characterized by recurrent febrile abdominal pain. Helicobacter pylori infection (HPI), one of the most frequent infections worldwide, can mimic an FMF attack. OBJECTIVES Identify FMF patients with HPI in a cohort of French FMF patients and the literature and identify features allowing to distinguish HPI from an FMF attack. METHODS A retrospective study of all HPI cases was performed on the cohort of FMF patients fulfilling the Livneh criteria from the French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA). A systematic literature review of HPI in FMF patients was conducted according to the PRISMA guidelines. RESULTS Eight French patients developed HPI, whose symptoms of epigastralgia, diarrhea, anorexia/weight loss, and nausea/vomiting differed from their typical abdominal FMF attacks. A total of 112 FMF patients with HPI have been described in the literature, including 61 adults. Diagnosis of HPI was made by gastroscopy (n = 43), labelled urea test (n = 55) or IgG serology by ELISA (n = 12). When performed, C-reactive protein was always elevated. Ten cases of interaction between colchicine and antibiotic therapy for HPI (clarithromycin (n = 9) and azithromycin (n = 1)) were reported. CONCLUSION We described a total of 120 patients with typical FMF and HPI. When FMF patients develop atypical abdominal symptoms, upper gastrointestinal endoscopy with biopsies is essential to eliminate underlying HPI. Untreated HPI can lead to misdiagnosis of colchicine resistance with inappropriate prescription of an interleukin-1 inhibitor at a non-negligible cost.
Collapse
Affiliation(s)
- Carole Lacout
- Department of Internal Medicine, AP-HP, Tenon Hospital, Sorbonne University, Paris, France.,Department of Internal Medicine, Angers Hospital, Angers, France
| | - Léa Savey
- Department of Internal Medicine, AP-HP, Tenon Hospital, Sorbonne University, Paris, France
| | - Rim Bourguiba
- Department of Internal Medicine, AP-HP, Tenon Hospital, Sorbonne University, Paris, France
| | - Irina Giurgea
- Department of Genetic, APHP, Trousseau Hospital, Sorbonne University, Paris, France
| | - Serge Amselem
- Department of Genetic, APHP, Trousseau Hospital, Sorbonne University, Paris, France
| | - Nadia Hoyeau
- Department of histology, APHP, Saint-Antoine Hospital, Paris, France
| | - Joris Galland
- Department of Internal Medicine, AP-HP, Tenon Hospital, Sorbonne University, Paris, France
| | - Xavier Amiot
- Department of Gastroenterology, Tenon Hospital, Paris, France
| | - Gilles Grateau
- Department of Internal Medicine, AP-HP, Tenon Hospital, Sorbonne University, Paris, France
| | | | | |
Collapse
|
36
|
Delaleu J, Deshayes S, Rodrigues F, Savey L, Rivière E, Martin Silva N, Aouba A, Amselem S, Rabant M, Grateau G, Giurgea I, Georgin-Lavialle S. Tumor necrosis factor receptor-1 assciated periodic syndrome (TRAPS) related AA amyloidosis: a national case series and systematic review. Rheumatology (Oxford) 2021; 60:5775-5784. [PMID: 33715002 DOI: 10.1093/rheumatology/keab252] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 03/03/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES Tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory disorder associated with mutations in the TNF receptor super family 1A (TNFRSF1A) gene. AA amyloidosis (AA) is the most severe complication of TRAPS. To study the occurrence and prognosis of AA in TRAPS, we conducted a retrospective study of all French cases and a systematic literature review. METHODS This case series includes TRAPS patients followed by our center from 2000 to 2020 presenting with histologically confirmed AA. We conducted a systematic literature review on the PubMed and Embase databases for articles published up February 2021 following the PRISMA guidelines and using the keywords: amyloidoisis, amyloid, TNF receptor-associated periodic syndrome, TNF Receptor-associated Periodic Syndrome, Tumor necrosis factor receptor-associated periodic syndrome, TRAPS, TNFRSF1A, Familial Hibernian fever and Hibernian Familial Fever. RESULTS A total of 41 TRAPS with AA were studied: 3 new patients and 38 cases from the literature. AA diagnosis preceded that of TRAPS in 96% of cases, and 17/36 (47%) required renal replacement therapy. Death occurred in 5/36 (14%) with a median follow-up of 23 months. Effect of biologics on AA were available for 21 regimens in 19 patients: 10 improved renal function, 7 stabilized and 4 worsened. Four patients (36% of transplanted patients) relapse AA on kidney graft (only one under etanercept). CONCLUSION TRAPS is revealed by AA in most cases. Therefore, clinical features of TRAPS should be screened for in AA patients. IL-1 antagonist can help to normalize inflammation and to preserve renal function.
Collapse
Affiliation(s)
- Jérémie Delaleu
- Sorbonne University, GRC GRAASU, Department of Internal Medicine, APHP, Tenon Hospital, Paris, France.,National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CeRéMAIA)
| | - Samuel Deshayes
- Department of Internal Medicine, Normandie Univ, CHU de Caen Normandie, Caen, France
| | - Francois Rodrigues
- Sorbonne University, GRC GRAASU, Department of Internal Medicine, APHP, Tenon Hospital, Paris, France.,National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CeRéMAIA)
| | - Lea Savey
- Sorbonne University, GRC GRAASU, Department of Internal Medicine, APHP, Tenon Hospital, Paris, France.,National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CeRéMAIA)
| | - Etienne Rivière
- Department of Internal Medicine, CHU de Bordeaux, Haut-Lévêque Hospital, Pessac, France
| | - Nicolas Martin Silva
- Department of Internal Medicine, Normandie Univ, CHU de Caen Normandie, Caen, France
| | - Achille Aouba
- Department of Internal Medicine, Normandie Univ, CHU de Caen Normandie, Caen, France
| | - Serge Amselem
- National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CeRéMAIA).,Sorbonne University, Genetic Laboratory, APHP, Trousseau Hospital, Paris, France
| | - Marion Rabant
- Department of Pathology, APHP, Necker Hospital, Paris, France
| | - Gilles Grateau
- Sorbonne University, GRC GRAASU, Department of Internal Medicine, APHP, Tenon Hospital, Paris, France.,National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CeRéMAIA)
| | - Irina Giurgea
- National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CeRéMAIA).,Sorbonne University, Genetic Laboratory, APHP, Trousseau Hospital, Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne University, GRC GRAASU, Department of Internal Medicine, APHP, Tenon Hospital, Paris, France.,National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CeRéMAIA)
| |
Collapse
|
37
|
Georgin-Lavialle S, Abe E, Larabi A, Savey L, Ducharme-Bénard S, Hentgen V, Grateau G, Alvarez JC. Could we measure hair colchicine to assess colchicine observance in familial Mediterranean fever? Rheumatology (Oxford) 2021; 60:1563-1564. [PMID: 33347575 DOI: 10.1093/rheumatology/keaa811] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Sophie Georgin-Lavialle
- Tenon hospital, Internal medicine department, Sorbonne University, AP-HP, Paris, France.,French National Reference Center for Autoinflammatory Diseases, AA Amyloidosis (CEREMAIA), Paris, France
| | - Emuri Abe
- Paris Saclay University, Pharmacology and Toxicology Laboratory, Inserm U-1173, Raymond Poincaré hospital, AP-HP, Garches, France
| | - Amine Larabi
- Paris Saclay University, Pharmacology and Toxicology Laboratory, Inserm U-1173, Raymond Poincaré hospital, AP-HP, Garches, France
| | - Léa Savey
- Tenon hospital, Internal medicine department, Sorbonne University, AP-HP, Paris, France.,French National Reference Center for Autoinflammatory Diseases, AA Amyloidosis (CEREMAIA), Paris, France
| | - Stéphanie Ducharme-Bénard
- Tenon hospital, Internal medicine department, Sorbonne University, AP-HP, Paris, France.,French National Reference Center for Autoinflammatory Diseases, AA Amyloidosis (CEREMAIA), Paris, France
| | - Véronique Hentgen
- French National Reference Center for Autoinflammatory Diseases, AA Amyloidosis (CEREMAIA), Paris, France.,General Pediatric Department, Versailles Hospital, Versailles, France
| | - Gilles Grateau
- Tenon hospital, Internal medicine department, Sorbonne University, AP-HP, Paris, France.,French National Reference Center for Autoinflammatory Diseases, AA Amyloidosis (CEREMAIA), Paris, France
| | - Jean-Claude Alvarez
- Paris Saclay University, Pharmacology and Toxicology Laboratory, Inserm U-1173, Raymond Poincaré hospital, AP-HP, Garches, France
| |
Collapse
|
38
|
Camilli G, Bohm M, Piffer AC, Lavenir R, Williams DL, Neven B, Grateau G, Georgin-Lavialle S, Quintin J. β-Glucan-induced reprogramming of human macrophages inhibits NLRP3 inflammasome activation in cryopyrinopathies. J Clin Invest 2021; 130:4561-4573. [PMID: 32716363 DOI: 10.1172/jci134778] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Accepted: 05/20/2020] [Indexed: 12/14/2022] Open
Abstract
Exposure of mononuclear phagocytes to β-glucan, a naturally occurring polysaccharide, contributes to the induction of innate immune memory, which is associated with long-term epigenetic, metabolic, and functional reprogramming. Although previous studies have shown that innate immune memory induced by β-glucan confers protection against secondary infections, its impact on autoinflammatory diseases, associated with inflammasome activation and IL-1β secretion, remains poorly understood. In particular, whether β-glucan-induced long-term reprogramming affects inflammasome activation in human macrophages in the context of these diseases has not been explored. We found that NLRP3 inflammasome-mediated caspase-1 activation and subsequent IL-1β production were reduced in β-glucan-reprogrammed macrophages. β-Glucan acted upstream of the NLRP3 inflammasome by preventing potassium (K+) efflux, mitochondrial ROS (mtROS) generation, and, ultimately, apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization and speck formation. Importantly, β-glucan-induced memory in macrophages resulted in a remarkable attenuation of IL-1β secretion and caspase-1 activation in patients with an NLRP3-associated autoinflammatory disease, cryopyrin-associated periodic syndromes (CAPS). Our findings demonstrate that β-glucan-induced innate immune memory represses IL-1β-mediated inflammation and support its potential clinical use in NLRP3-driven diseases.
Collapse
Affiliation(s)
- Giorgio Camilli
- Immunology of Fungal Infections, Department of Mycology, Institut Pasteur, Paris, France
| | - Mathieu Bohm
- Immunology of Fungal Infections, Department of Mycology, Institut Pasteur, Paris, France
| | - Alícia Corbellini Piffer
- Immunology of Fungal Infections, Department of Mycology, Institut Pasteur, Paris, France.,Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Rachel Lavenir
- Immunology of Fungal Infections, Department of Mycology, Institut Pasteur, Paris, France
| | - David L Williams
- Department of Surgery, Center of Excellence in Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA
| | - Benedicte Neven
- Pediatric Hematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France
| | - Gilles Grateau
- Service de Médecine Interne et Centre de Références des Maladies Auto-inflammatoires et des Amyloses Inflammatoires, Hôpital Tenon, Sorbonne Université, Paris, France
| | - Sophie Georgin-Lavialle
- Service de Médecine Interne et Centre de Références des Maladies Auto-inflammatoires et des Amyloses Inflammatoires, Hôpital Tenon, Sorbonne Université, Paris, France
| | - Jessica Quintin
- Immunology of Fungal Infections, Department of Mycology, Institut Pasteur, Paris, France
| |
Collapse
|
39
|
Fayand A, Savey L, Ducharme-Bénard S, Grateau G, Georgin-Lavialle S. Prescription of interleukin-1 inhibitors in a French adult cohort of familial Mediterranean fever. Eur J Intern Med 2021; 84:109-111. [PMID: 33223329 DOI: 10.1016/j.ejim.2020.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 10/26/2020] [Accepted: 11/02/2020] [Indexed: 10/23/2022]
Affiliation(s)
- Antoine Fayand
- Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France; French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA)
| | - Léa Savey
- Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France; French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA)
| | - Stéphanie Ducharme-Bénard
- Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France; Service de médecine interne, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
| | - Gilles Grateau
- Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France; French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA)
| | - Sophie Georgin-Lavialle
- Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France; French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA)..
| |
Collapse
|
40
|
Delplanque M, Galicier L, Oziol E, Ducharme-Bénard S, Oksenhendler E, Buob D, Grateau G, Boutboul D, Georgin-Lavialle S. AA Amyloidosis Secondary to Primary Immune Deficiency: About 40 Cases Including 2 New French Cases and a Systematic Literature Review. J Allergy Clin Immunol Pract 2021; 9:745-752.e1. [PMID: 33007500 DOI: 10.1016/j.jaip.2020.09.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 09/08/2020] [Accepted: 09/09/2020] [Indexed: 06/11/2023]
Abstract
BACKGROUND Primary immune deficiencies (PIDs) are a heterogeneous group of disorders resulting from defects in immune system. They lead to increased susceptibility to infections and immune dysregulation. The resulting chronic inflammation can induce long-term complications, including AA amyloidosis (AAA). OBJECTIVES To present the French cases of PID-related AAA and perform a systematic literature review to determine its main features and predisposing factors. METHODS A systematic literature review was performed by searching MEDLINE up until 2019. New French cases were identified with the help of the Reference Center for Auto-Inflammatory Diseases and AA Amyloidosis and the Reference Center for Hereditary Immune Deficiencies. RESULTS Forty patients were identified including 2 new French cases. PIDs were varied: immunoglobulin deficits (n = 30), chronic granulomatous disease (n = 3), hyper-IgM syndrome (n = 3), hereditary complete C4 deficiency (n = 1), leucocyte adhesion deficiency type 1 (n = 1), hyper-IgE syndrome (n = 1), and Chediak-Higashi syndrome (n = 1). The mean age at PID diagnosis was 22.2 ± 16.02 years. Renal involvement was the most common manifestation of AAA (80%). Infections were extremely heterogeneous; bacterial infection with pulmonary involvement was the most frequent. Bronchiectasis was particularly common (52.5%). The delay between the first symptoms of PID and AAA diagnosis was 16.18 ± 7 years. Thirteen concomitant diagnoses were made. Twenty patients died during follow-up. CONCLUSION AAA is a rare life-threatening complication of PID, especially in cases of long diagnostic and therapeutic delays. Bronchiectasis should be considered as a warning sign of chronic inflammation and increased risk of AAA.
Collapse
Affiliation(s)
- Marion Delplanque
- Sorbonne Université, AP-HP, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), GRC-28 (Groupe de recherche clinique amylose AA Sorbonne univeristé), Paris, France
| | - Lionel Galicier
- Service d'Immunopathologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France
| | - Eric Oziol
- Service de Médecine Interne, Centre Hospitalier de Béziers, Béziers, France
| | | | - Eric Oksenhendler
- Service d'Immunopathologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France
| | - David Buob
- Sorbonne Université, AP-HP, Hôpital Tenon, Service d'Anatomie et Cytologie pathologiques, Paris, France
| | - Gilles Grateau
- Sorbonne Université, AP-HP, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), GRC-28 (Groupe de recherche clinique amylose AA Sorbonne univeristé), Paris, France
| | - David Boutboul
- Service d'Immunopathologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, AP-HP, Hôpital Tenon, Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), GRC-28 (Groupe de recherche clinique amylose AA Sorbonne univeristé), Paris, France.
| |
Collapse
|
41
|
Hentgen V, Koné-Paut I, Belot A, Galeotti C, Grateau G, Carbasse A, Pagnier A, Pillet P, Delord M, Hofer M, Georgin-Lavialle S. Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort. Front Pharmacol 2021; 11:568865. [PMID: 33505305 PMCID: PMC7832034 DOI: 10.3389/fphar.2020.568865] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 10/12/2020] [Indexed: 11/13/2022] Open
Abstract
Objectives: The major role of interleukin (IL)-1 in the pathogenesis of hereditary recurrent fever syndromes favored the employment of targeted therapies modulating IL-1 signaling. However the best use of IL1 inhibitors in terms of dosage is difficult to define at present. Methods: In order to better understand the use of IL1 inhibitors in a real-life setting, our study assessed the dosage regimens of French patients with one of the four main hereditary recurrent fever syndromes (Familial Mediterranean Fever (FMF), TNF receptor associated periodic syndrome (TRAPS), cryopyrin associated periodic fever (CAPS) and mevalonate kinase deficiency). The patients were retrieved retrospectively from the JIR cohort, an international platform gathering data of patients with pediatric inflammatory diseases. Results: Forty five patients of the JIR cohort with a hereditary recurrent fever syndrome had received at least once an IL1 inhibitor (anakinra or canakinumab). Of these, 43% received a lower dosage than the one suggested in the product recommendations, regardless of the type of the IL1 inhibitor. Especially patients with FMF and TRAPS seemed to need lower treatment regimens; in our cohort none of the FMF or TRAPS patients received an intensified dose of IL-inhibitor. On-demand treatment with a short half-life IL-1 inhibitor has also been used successfully for some patients with one of these two conditions The standard dose was given to 42% of the patients; whereas an intensified dose of IL-1 inhibitors was given to 15% of the patients (44% of CAPS patients and 17% of mevalonate kinase deficiency patients). In our cohort each individual patient’s need for treatment seemed highly variable, ranging from on demand treatment regimens to intensified dosage maintenance therapies depending on the activity and the severity of the underlying disease. Conclusion: IL-1 inhibitors are a good treatment option for patients with a hereditary recurrent fever syndrome, but the individual need of the dosage of IL-1 inhibitors to control the disease effectively seems highly variable. Severity, activity but also the type of the underlying disease, belong to the parameters underpinning the treat-to-target strategy implemented in an everyday life practice.
Collapse
Affiliation(s)
- Véronique Hentgen
- Department of Pediatrics, National Reference Center for Auto-inflammatory Diseases and Amyloidosis, CEREMAIA, Versailles Hospital, Versailles, France
| | - Isabelle Koné-Paut
- Department of Pediatric Rheumatology National Reference Center for Auto-Inflammatory Diseases and Amyloidosis, CEREMAIA, CHU du Kremlin Bicêtre, University of Paris Sud Saclay, UVSQ, Le Kremlin Bicêtre, France
| | - Alexandre Belot
- Pediatric Nephrology, Rheumatology, Dermatology, HFME, Hospices Civils de Lyon, National Referee Centre RAISE, & INSERM U1111, Université de Lyon, Lyon, France
| | - Caroline Galeotti
- Department of Pediatric Rheumatology National Reference Center for Auto-Inflammatory Diseases and Amyloidosis, CEREMAIA, CHU du Kremlin Bicêtre, University of Paris Sud Saclay, UVSQ, Le Kremlin Bicêtre, France
| | - Gilles Grateau
- Department of Internal Medicine, National Reference Center for Auto-Inflammatory Diseases and Amyloidosis, CEREMAIA, Tenon Hospital, AP-HP, Sorbonne University, Paris, France
| | - Aurelia Carbasse
- Department of Pediatrics, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France
| | - Anne Pagnier
- Department of Pediatrics, CHU de Grenoble, Grenoble, France
| | - Pascal Pillet
- Department of Pediatrics, Hôpital des Enfants, CHRU Bordeaux, Bordeaux, France
| | - Marc Delord
- Direction de La Recherche Clinique et de L'Innovation (DRCI) Versailles Hospital, Versailles, France
| | - Michael Hofer
- Unité Romande D'Immuno-Rhumatologie Pédiatrique, CHUV, University of Lausanne, Lausanne, Switzerland
| | - Sophie Georgin-Lavialle
- Department of Internal Medicine, National Reference Center for Auto-Inflammatory Diseases and Amyloidosis, CEREMAIA, Tenon Hospital, AP-HP, Sorbonne University, Paris, France
| |
Collapse
|
42
|
Terré A, Deshayes S, Savey L, Grateau G, Georgin-Lavialle S. Cause of death and risk factors for mortality in AA amyloidosis: A French retrospective study. Eur J Intern Med 2020; 82:130-132. [PMID: 32807649 DOI: 10.1016/j.ejim.2020.08.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 08/10/2020] [Indexed: 12/29/2022]
Affiliation(s)
- Alexandre Terré
- Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France
| | - Samuel Deshayes
- Normandie Univ, UNICAEN, CHU de Caen Normandie, Department of Internal Medicine, Caen 14000, France
| | - Léa Savey
- Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France
| | - Gilles Grateau
- Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France; Inserm UMRS_933, et laboratoire de génétique, Trousseau hospital, AP-HP, Faculté de médecine - Sorbonne University, Paris, France
| | - Sophie Georgin-Lavialle
- Sorbonne University, AP-HP, Tenon hospital, Department of Internal Medicine, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Paris GRC -28, France; Inserm UMRS_933, et laboratoire de génétique, Trousseau hospital, AP-HP, Faculté de médecine - Sorbonne University, Paris, France.
| |
Collapse
|
43
|
Deshayes S, Bazille C, Giurgea I, Martin Silva N, Ollivier I, Dumont A, Trenec M, Elhani I, Amselem S, De Boysson H, Grateau G, Georgin-Lavialle S, Aouba A. Hépatopathie chronique dans le spectre clinique de l’haplo-insuffisance en A20 (HA20) : description clinique et histopathologique à partir d’une famille française porteuse d’une nouvelle mutation de TNFAIP3. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Fayand A, Chasset F, David B, Grateau G, Touitou I, Guilaine B, Georgin-Lavialle S. La place de l’interniste dans le diagnostic du déficit en adénosine déaminase 2 à l’âge adulte : à propos de 233 cas dont 12 patients français. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Bourguiba R, Savey L, Aouba A, Deshayes S, Fain O, Martin-Silva N, Hentgen V, Desdoits A, Grateau G, Giurgea I, Georgin-Lavialle S. [Periodic fever syndrome associated with mutations in the TNF type 1 receptor gene: A differential diagnosis of familial Mediterranean fever that should not be overlooked in patients of Mediterranean origin]. Rev Med Interne 2020; 42:459-464. [PMID: 33131906 DOI: 10.1016/j.revmed.2020.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 08/23/2020] [Accepted: 08/30/2020] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Tumor Necrosis Factor Type 1 Receptor Associated Periodic Syndrome (TRAPS) is a rare autosomal dominant autosomal autoinflammatory disease associated with mutations in the TNF type 1 receptor gene (TNFRSF1A). It is characterized by relatively long recurrent febrile seizures with an average duration of 7 days accompanied by arthralgia, myalgia, and usually a rash. In a patient of Mediterranean origin with recurrent fever, familial Mediterranean fever is the first diagnosis to be suspected by argument of frequency. METHODS A retrospective observational study was conducted on patients from Mediterranean origin followed for TRAPS and included in the "Juvenile Inflammatory Rheumatism" (JIR) observational cohort in the national French autoinflammatory center. The age of onset of symptoms, age of diagnosis, number of years of wandering and treatments received were collected for each index case. RESULTS Nine patients from 6 families of Mediterranean origin were included. A molecular diagnosis confirmed TRAPS in all patients. The median age at diagnosis was 26 years, the mean number of years of wandering was 17 years. The diagnosis of FMF was made first in all patients. AA amyloidosis revealed TRAPS in 2 patients. Colchicine was started without any efficacy in all cases. Five patients were treated with interleukin-1 inhibitory biotherapy with 100% efficacy. CONCLUSION In a patient of Mediterranean origin presenting with recurrent febrile abdominal pain of AA amyloidosis, the first diagnosis to be suspected is FMF. Long relapses, dominant transmission, a non-Mediterranean relative, and the ineffectiveness of colchicine should evoke TRAPS.
Collapse
Affiliation(s)
- R Bourguiba
- Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France
| | - L Savey
- Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France
| | - A Aouba
- Service de médecine interne, Unicaen, CHU de Caen Normandie, Normandie université, 14000 Caen, France
| | - S Deshayes
- Service de médecine interne, Unicaen, CHU de Caen Normandie, Normandie université, 14000 Caen, France
| | - O Fain
- Service de médecine interne, Sorbonne université, hôpital Saint-Antoine, AP-HP, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - N Martin-Silva
- Service de médecine interne, Unicaen, CHU de Caen Normandie, Normandie université, 14000 Caen, France
| | - V Hentgen
- Service de pédiatrie générale, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), hôpital André-Mignot, Versailles, France
| | - A Desdoits
- Service de pédiatrie générale, CHU de Caen Normandie, 14000 Caen, France
| | - G Grateau
- Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France
| | - I Giurgea
- Laboratoire de génétique médicale, Inserm U933, Sorbonne université, hôpital Trousseau, Paris, France
| | - S Georgin-Lavialle
- Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France.
| |
Collapse
|
46
|
Bourguiba R, Delplanque M, Vinit C, Ackermann F, Savey L, Grateau G, Hentgen V, Georgin-Lavialle S. Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis 2020; 80:539-540. [PMID: 33139307 DOI: 10.1136/annrheumdis-2020-218707] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 10/23/2020] [Accepted: 10/27/2020] [Indexed: 02/01/2023]
Affiliation(s)
- Rim Bourguiba
- Sorbonne Université, AP-HP, DMU3ID, Tenon hospital, Internal medicine department, national reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), Paris, France
| | - Marion Delplanque
- Sorbonne Université, AP-HP, DMU3ID, Tenon hospital, Internal medicine department, national reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), Paris, France
| | - Caroline Vinit
- General pediatry department, Versaille hospital, André-Mignot, General pediatry department, National reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), versailles, France
| | - Felix Ackermann
- Department of Internal Medicine, Hopital Foch, Sursennes, France
| | - Léa Savey
- Sorbonne Université, AP-HP, DMU3ID, Tenon hospital, Internal medicine department, national reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), Paris, France
| | - Gilles Grateau
- Sorbonne Université, AP-HP, DMU3ID, Tenon hospital, Internal medicine department, national reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), Paris, France
| | - Veronique Hentgen
- General pediatry department, Versaille hospital, André-Mignot, General pediatry department, National reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), versailles, France
| | - Sophie Georgin-Lavialle
- Sorbonne Université, AP-HP, DMU3ID, Tenon hospital, Internal medicine department, national reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), Paris, France
| |
Collapse
|
47
|
Magnotti F, Malsot T, Georgin-Lavialle S, Abbas F, Martin A, Belot A, Fauter M, Rabilloud M, Gerfaud-Valentin M, Sève P, Duquesne A, Hot A, Durupt S, Savey L, Giurgea I, Grateau G, Henry T, Jamilloux Y. Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor. Ann Rheum Dis 2020; 80:128-132. [PMID: 33037005 DOI: 10.1136/annrheumdis-2020-218366] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Revised: 08/27/2020] [Accepted: 08/30/2020] [Indexed: 01/21/2023]
Abstract
BACKGROUND AND OBJECTIVE Familial Mediterranean fever (FMF) is the most frequent hereditary autoinflammatory disease. Its diagnosis relies on a set of clinical criteria and a genetic confirmation on identification of biallelic pathogenic MEFV variants. MEFV encodes pyrin, an inflammasome sensor. Using a kinase inhibitor, UCN-01, we recently identified that dephosphorylation of FMF-associated pyrin mutants leads to inflammasome activation. The aim of this study was to assess whether quantifying UCN-01-mediated inflammasome activation could discriminate FMF patients from healthy donors (HD) and from patients with other inflammatory disorders (OID). METHODS Real-time pyroptosis and IL-1β secretion were monitored in response to UCN-01 in monocytes from FMF patients (n=67), HD (n=71) and OID patients (n=40). Sensitivity and specificity of the resulting diagnostic tests were determined by receiver operating characteristic curve analyses. RESULTS Inflammasome monitoring in response to UCN-01 discriminates FMF patients from other individuals. Pyroptosis assessment leads to a fast FMF diagnosis while combining pyroptosis and IL-1β dosage renders UCN-01-based assays highly sensitive and specific. UCN-01-triggered monocytes responses were influenced by MEFV gene dosage and MEFV mutations in a similar way as clinical phenotypes are. CONCLUSIONS UCN-01-based inflammasome assays could be used to rapidly diagnose FMF, with high sensitivity and specificity.
Collapse
Affiliation(s)
- Flora Magnotti
- Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard-Lyon 1, CNRS, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Tiphaine Malsot
- Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard-Lyon 1, CNRS, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Sophie Georgin-Lavialle
- Internal Medicine, Tenon Hospital, AP-HP, Paris, France.,CEREMAIA (Centre de Référence des Maladies Autoinflammatoires et des Amyloses), Paris, France
| | - Fatima Abbas
- Biostatistics, Pôle de Santé Publique,CNRS UMR5308, Hospices Civils de Lyon, Lyon, France
| | - Amandine Martin
- Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard-Lyon 1, CNRS, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Alexandre Belot
- Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard-Lyon 1, CNRS, Ecole Normale Supérieure de Lyon, Lyon, France.,CEREMAIA (Centre de Référence des Maladies Autoinflammatoires et des Amyloses), Paris, France.,Department of Paediatric Nephrology, Rheumatology, Dermatology, Hôpital Femme-Mère Enfant, Université Claude Bernard-Lyon 1, Hospices Civils de Lyon, Bron, France
| | - Maxime Fauter
- Internal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, Lyon, France.,Internal Medicine, Hospices Civils de Lyon, Lyon, France
| | - Muriel Rabilloud
- Biostatistics, Pôle de Santé Publique,CNRS UMR5308, Hospices Civils de Lyon, Lyon, France
| | | | - Pascal Sève
- Internal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Agnes Duquesne
- Department of Paediatric Nephrology, Rheumatology, Dermatology, Hôpital Femme-Mère Enfant, Université Claude Bernard-Lyon 1, Hospices Civils de Lyon, Bron, France
| | - Arnaud Hot
- Internal Medicine, University Hospital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Stephane Durupt
- Internal Medicine, University Hospital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Léa Savey
- Internal Medicine, Tenon Hospital, AP-HP, Paris, France
| | - Irina Giurgea
- Genetics, Armand-Trousseau Hospital, APHP, Sorbonne University, Paris, Île-de-France, France
| | - Gilles Grateau
- Internal Medicine, Tenon Hospital, AP-HP, Paris, France.,CEREMAIA (Centre de Référence des Maladies Autoinflammatoires et des Amyloses), Paris, France
| | - Thomas Henry
- Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard-Lyon 1, CNRS, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Yvan Jamilloux
- Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard-Lyon 1, CNRS, Ecole Normale Supérieure de Lyon, Lyon, France .,Internal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
48
|
Terré A, Knebelmann B, Buob D, Rabant M, Lidove O, Deshayes S, Ouali N, Grateau G, Georgin-Lavialle S. AA amyloidosis associated with Fabry disease. Int J Clin Pract 2020; 74:e13577. [PMID: 32515527 DOI: 10.1111/ijcp.13577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 06/03/2020] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Fabry disease (FD) is the second most common lysosomal storage disorder, carrying a large morbidity and mortality. It has been recently reported that lysosomal storage disorders could cause inflammation and, subsequently, AA amyloidosis (AAA). Our aim was to describe AAA cases occurring in the course of FD. PATIENTS AND METHODS We described two patients displaying both AAA and FD and an additional case from the literature. RESULTS Three female patients originating from Europe (n = 2) and Algeria (n = 1) harboured heterozygous GLA mutations. The median age at AAA diagnosis was 61 years old. The diagnosis of Fabry was made before the diagnosis of AAA (n = 1) or concomitantly (n = 2). At AAA diagnosis, two patients displayed a nephrotic syndrome; all had inflammation. CONCLUSION Fabry disease can be associated with AAA, suggesting that an inflammatory component could exist in this genetic disease.
Collapse
Affiliation(s)
- Alexandre Terré
- Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France
| | - Bertrand Knebelmann
- Service de Néphrologie-Dialyse Adultes, Centre de Reference Maladies Rénales Héréditaires MARHEA, AP-HP, Hôpital Universitaire Necker, Université Paris Descartes, Paris, France
| | - David Buob
- Service d'Anatomie Pathologique, AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France
| | - Marion Rabant
- Laboratoire d'Anatomie et de Cytologie Pathologiques, Hôpital Universitaire Necker, AP-HP, Paris, France
| | - Olivier Lidove
- Service de médecine interne, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France
- Reference Centre for Lysosomal Storage Disorders (CRML, site Avron), Groupe Hospitalier Diaconesses Croix-Saint-Simon, Paris, France
| | - Samuel Deshayes
- Department of Internal Medicine, UNICAEN, CHU de Caen Normandie, Normandie Univ, Caen, France
| | - Nacera Ouali
- Inserm UMRS_933, hôpital Trousseau, Paris, France
| | - Gilles Grateau
- Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France
- Inserm UMRS_933, hôpital Trousseau, Paris, France
| | - Sophie Georgin-Lavialle
- Service de médecine interne, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France
- Inserm UMRS_933, hôpital Trousseau, Paris, France
| |
Collapse
|
49
|
Ducharme-Bénard S, Steichen O, Savey L, Hentgen V, Aouba A, Grateau G, Georgin-Lavialle S. Attacks of TNF-receptor associated periodic syndrome are associated with higher inflammatory markers than familial Mediterranean fever. Clin Exp Rheumatol 2020; 38 Suppl 127:131. [PMID: 33331272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Accepted: 11/16/2020] [Indexed: 06/12/2023]
Affiliation(s)
| | - Olivier Steichen
- Service de Médecine Interne, Hôpital Tenon, Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, France
| | - Léa Savey
- Service de Médecine Interne, Hôpital Tenon, Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, France
| | | | - Achille Aouba
- Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Caen-Normandie, Caen, France
| | - Gilles Grateau
- Service de Médecine Interne, Hôpital Tenon, Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, France
| | - Sophie Georgin-Lavialle
- Service de Médecine Interne, Hôpital Tenon, Université Pierre et Marie Curie, Assistance Publique-Hôpitaux de Paris, France.
| |
Collapse
|
50
|
Rech JS, Yao K, Bachmeyer C, Bailleul S, Javier O, Grateau G, Lionnet F, Steichen O. Prognostic Value of Hyponatremia During Acute Painful Episodes in Sickle Cell Disease. Am J Med 2020; 133:e465-e482. [PMID: 32199810 DOI: 10.1016/j.amjmed.2020.02.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 11/22/2019] [Accepted: 02/14/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Low plasma sodium concentration has been recognized as a prognostic factor in several disorders but never evaluated in sickle cell disease. The present study evaluates its value at admission to predict a complication in adult patients with sickle cell disease hospitalized for an initially uncomplicated acute painful episode. METHODS The primary outcome of this retrospective study, performed between 2010 and 2015 in a French referral center for sickle cell disease, was a composite criterion including acute chest syndrome, intensive care unit transfer, red blood cell transfusion or inpatient death. Analyses were adjusted for age, sex, hemoglobin genotype and concentration, lactate dehydrogenase (LDH) concentration, and white blood cell count. RESULTS We included 1218 stays (406 patients). No inpatient death occurred during the study period. Hyponatremia (plasma sodium ≤135 mmol/L) at admission in the center was associated with the primary outcome (adjusted odds ratio [OR] 1.95, 95% confidence interval [CI] 1.3-2.91, P = 0.001), with acute chest syndrome (OR 1.95 [95% CI 1.2-3.17, P = 0.008]), and red blood cell transfusion (OR 2.71 [95% CI 1.58-4.65, P <0.001]) but not significantly with intensive care unit transfer (OR 1.83 [95% CI 0.94-3.79, P = 0.074]). Adjusted mean length of stay was longer by 1.1 days (95% CI 0.5-1.6, P <0.001) in patients with hyponatremia at admission. CONCLUSIONS Hyponatremia at admission in the medical department for an acute painful episode is a strong and independent prognostic factor of unfavorable outcome and, notably, acute chest syndrome. It could help targeting patients who may benefit from closer monitoring.
Collapse
Affiliation(s)
- Jean-Simon Rech
- Department of Internal Medicine, Sickle Cell Disease Reference Center, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Groupe de Recherche Clinique Drépanocytose Recherche à Paris Sorbonne Université, Sorbonne University, Paris, France
| | - Kan Yao
- Department of Information Systems, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Claude Bachmeyer
- Department of Internal Medicine, Sickle Cell Disease Reference Center, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Sophie Bailleul
- Department of Biochemistry, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Orlando Javier
- Department of Medical Information, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gilles Grateau
- Department of Internal Medicine, Sickle Cell Disease Reference Center, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Department of Medical Information, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - François Lionnet
- Department of Internal Medicine, Sickle Cell Disease Reference Center, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Groupe de Recherche Clinique Drépanocytose Recherche à Paris Sorbonne Université, Sorbonne University, Paris, France
| | - Olivier Steichen
- Department of Internal Medicine, Sickle Cell Disease Reference Center, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Groupe de Recherche Clinique Drépanocytose Recherche à Paris Sorbonne Université, Sorbonne University, Paris, France.
| |
Collapse
|